Therapeutic molecules that bind to LAG3
Bispecific antibodies targeting LAG-3 and PD-1 using single domain antibodies enhance T cell activation and immune response, addressing limitations of current therapies by selectively targeting tumor-specific cells and improving treatment efficacy.
Patent Information
- Application Number
- JP2024116130
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-02-16
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-06
AI Technical Summary
Current antibody-based therapies targeting LAG-3 and PD-1 pathways for treating cancer and other diseases have limited response rates, resistance issues, and safety concerns, necessitating improved methods to enhance T cell function and overcome overlapping immune checkpoint pathways.
Development of bispecific antibodies that bind to both LAG-3 and PD-1, specifically using single domain antibodies (sdAbs) to target tumor-specific cells with high affinity, thereby enhancing T cell activation and immune response.
The bispecific antibodies selectively target cells expressing both LAG-3 and PD-1, improving T cell function, overcoming resistance, and providing enhanced therapeutic efficacy compared to combination therapies, with improved safety profiles and increased response rates.
Smart Images

Figure 2024156719000026 
Figure 2024156719000027 
Figure 2024156719000028
Abstract
Description
[Technical field]
[0001] Antibody-based therapeutics have emerged as a key component of the treatment for a growing number of human malignancies in the areas of oncology, inflammatory diseases, infectious diseases, etc. In fact, antibodies are currently one of the best-selling drugs, with five of the top ten best-selling drugs being antibodies.
[0002] Lymphocyte activation gene 3 (LAG-3, LAG3, CD223) is a transmembrane protein of the immunoglobulin superfamily. It has four extracellular domains and shares homology with CD4 (Triebel 1990 J. Exp. Med. 171:1393-1405).
[0003] LAG-3 is expressed in CD4+ T cells, CD8+ T cells, T regulatory cells, B cells, NK cells and plasmacytoid dendritic cells (Huard 1994 Eur. J. Immunol. 24:3216-21; Grosso 2007 J. Clin. Invest. 117:3383-92; Huang 2004 Immunity. 21:503-13; Kieslow 2005 Eur. J. Immunol. 35:2081-88; Triebel 1990 J. Exp.Med. 171:1393-140; Castelli 2014 Oncoimmunology. 3:11).
[0004] The role of LAG-3 on T cells is to regulate T cell activation (Huard 1994 Eur. J. Immunol. 24:3216-21). LAG-3 binds to MHC class II, causing downregulation of CD4+ T cells (Huard 1996 Eur. J. Immunol. 26:1180-6). Upon T cell activation, surface expression of LAG-3 increases. Binding of LAG-3 dimers to ligands induces signaling through the intracellular KIEELE domain (Workman 2002 J.Immunol 169:5392-5), causing downregulation of T cell activity. Thus, LAG-3 functions to regulate responses to antigens, prevent overstimulation, and maintain immune homeostasis.
[0005] LAG-3 is composed of an intracellular signaling domain, a transmembrane domain, and four extracellular domains numbered 1-4 (Huard 1997 Proc. Natl. Acad. Sci. 94:5744-9). Domains 1-2 have been shown to associate with MHC class II ligands, with the tip of domain 1 (extra loop) forming the binding site (Huard 1997 Proc. Natl. Acad. Sci. 94:5744-9). LAG-3 can also associate with alternative ligands, galectin-3 and resectin, which induce its inhibitory signaling (Kouo 2015 Cancer Immunol Res. 3(4):412-23; Xu 2014 Cancer Res 74(13):3418-28). Engagement of galectin-3 on cells or in the extracellular matrix can downregulate T cells that do not normally bind MHC class II, such as CD8+ T cells, and thus blockade of this ligand may serve as a mechanism to enhance a broad range of T cell functions.
[0006] Antibodies that bind to LAG-3 have therapeutic potential. In mice, anti-LAG-3 antibodies reverse functionally unresponsive T cells and slow tumor progression (Grosso 2007 J. Clin. Invest. 117: 3383-92). LAG-3 is expressed in human tumor-infiltrating lymphocytes, and this localization blocks the preferred pathway for stimulating these cells (Matsuzaki 2010 PNAS 107(17):7875-80).
[0007] Programmed Death 1 (PD-1) protein is encoded by the PDCD1 gene and is expressed as a 55 kDa type I transmembrane protein (Agata 1996 Int Immunol 8(5):765-72). PD-1 is an immunoglobulin superfamily member (Ishida 1992 EMBO 11(11):3887-95) and is an inhibitory member of the extended CD28 / CTLA-4 family of T cell regulators. Other members of this family include CD28, CTLA-4, ICOS, and BTLA. PD-1 exists as a monomer and lacks the unpaired cysteine residue characteristic of other CD28 family members (Zhang 2004 Immunity 20:337-47). Its cytoplasmic domain contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs) that are phosphorylated during signal transduction (Riley 2009 Immunol Rev 229(1):114-25).
[0008] PD-1 is expressed in B cells, T cells and monocytes (Agata 1996). The role of PD-1 in maintaining immunological self-tolerance was demonstrated in PDCD1- / - mice that develop autoimmune disease (Nishimura 1999 Immunity 11:141-51, Nishimura 2001 Science 291(5502):319-22). Thus, the PD-1 pathway regulates antigen responses, balancing autoimmunity and tolerance.
[0009] Both LAG-3 and PD-1 regulate T cell activation. Their binding to ligands leads to inhibition of T cell activation and regulation of antigen-specific responses. PD-1 has two ligands that mediate its regulatory function. PD-L1 (B7-H1) is expressed on dendritic cells, macrophages, resting B cells, bone marrow-derived mast cells and T cells, and non-hematopoietic cell lineages (reviewed in Francisco 2010 Immunol Rev 236:219-42). PD-L2 (B7-DC) is mainly expressed on dendritic cells and macrophages (Tseng 2001 J Exp Med 193(7):839-45). Binding of the ligand to PD-1 crosslinks PD-1 and clusters it in the T-cell receptor (TCR) complex within the immune synapse (Yokosuka 2012 J Exp Med 209(9):1201-17). Within the cytoplasm of the T cell, the PD-1 signaling domains ITIM and ITSM are phosphorylated. This induces Src homology 2 domain-containing tyrosine phosphatases (SHP1 / 2) that attenuate various components of T-cell receptor (TCR) signaling. Binding of the LAG-3 dimer to the ligand induces signaling through the intracellular KIEELE domain (Workman 2002 J.Immunol 169:5392-5). Signaling suppresses T-cell activation, thereby causing a decrease in cytokine responses, proliferation and cytolytic activity. Blocking these pathways means that T-cell function can be restored, allowing for the restoration of antigen- or tumor-specific cellular responses.
[0010] Antibodies that block the PD-1:PD-L1 interaction are used in the medical setting for the treatment of oncology and non-cancer diseases, but are limited by low response rates. There is a need to increase the proportion of patients who benefit from such blocking therapies, address resistance to treatment, improve safety profiles, and overcome overlapping pathways. Combination therapies are used to improve responses to PD-1 blockade. Anti-LAG-3 antibodies are currently being evaluated in clinical trials as single agents and in combination with PD-1 pathway blocking antibodies. One reason combination therapy may be beneficial is that single agent checkpoint blockade leads to compensatory upregulation of other checkpoints (Huang 2017, Oncoimmunol 6(1) e1249561).
[0011] LAG-3 specific antibodies are known in the art and are in clinical trials for cancer treatment (e.g., NCT02061761, NCT02460224). However, potent blockade and improved response rates are needed. There is also a need to provide agents that bind to LAG-3 and block LAG-3 signaling and can be combined with other agents, such as immunotherapeutic agents, to achieve beneficial therapeutic effects. In particular, bispecific antibodies that bind to both PD-1 and LAG-3 and bind to these receptors on exhausted tumor-specific cells may enhance the function of such cells and cause tumor regression. Bispecific antibodies that bind to both PD-1 and LAG-3 have an advantage over combination therapy because the use of the latter universally blocks each target on cells expressing either target. On the other hand, bispecific antibodies target cells expressing both targets and can better target T cells with the most exhausted phenotype (expressing both PD-1 and LAG-3).
[0012] The present invention aims to address the need for alternative and improved therapeutic approaches and provides LAG-3 binding agents that can act as immune checkpoint inhibitors and can be used in immunotherapy for treating diseases such as cancer, e.g. in a bispecific format for dual blockade of PD-1 and LAG-3. Summary of the Invention
[0013] The present invention relates to proteins that bind to LAG-3, particularly variable heavy chains (V H The present invention relates to proteins comprising or consisting of anti-LAG-3 single domain antibodies (sdAbs), such as the LAG-3 single domain antibodies (sdAbs) and their use in the treatment, prevention and detection of disease.
[0014] In one embodiment, the present invention provides a method for the preparation of a medicament comprising administering to a subject a medicament the H The present invention relates to an isolated binding molecule comprising at least one single domain antibody (sdAb) that binds to human LAG-3, such as a single domain antibody. In one embodiment, the present invention relates to an isolated binding molecule comprising at least one single domain antibody (sdAb) that is bivalent for LAG-3 binding and binds to human LAG-3, in particular two sdAbs, two V H The present invention relates to an isolated binding molecule comprising or consisting of a single domain antibody.
[0015] The above-described binding molecules have several desirable properties, as described herein.
[0016] The binding molecules of the present invention bind to human LAG-3 and modulate the interaction of LAG-3 with its ligand. The binding molecules preferably bind to LAG-3 with high affinity and block the functional interaction of LAG-3 with its ligand as described below. In some embodiments, the binding molecules of the present invention can stimulate or enhance T cell activation. In some embodiments, the binding molecules can be useful for stimulating or enhancing immune responses and / or treating subjects suffering from cancer or other diseases.
[0017] The anti-LAG-3 V H The sdAbs exhibit many advantageous properties. In particular, the sdAbs of the invention can be used as functional building blocks in multivalent binding molecules, e.g., multispecific molecules, i.e., molecules that bind LAG-3 and have one or more other antigen binding sites. Also, two anti-LAG-3 V HThe sdAbs may be combined in fusion proteins to provide an enhanced effect as described herein.
[0018] Thus, the present invention also provides at least one anti-LAG-3 V H Single domain antibodies, preferably two anti-LAG-3 V H Concerning multivalent and / or multispecific binding agents, including single domain antibodies.
[0019] In one embodiment, the present invention provides antibodies that bind, e.g., simultaneously bind, LAG-3 and PD-1 present on the same cell and that bind at least one anti-LAG-3 V H Single domain antibodies, preferably two anti-LAG-3 V H In another embodiment, the present invention relates to a multispecific binding molecule comprising a single domain antibody. H In one embodiment, the multispecific binding molecule that simultaneously binds to LAG-3 and PD-1 comprises two anti-LAG-3 V and V H Single domain antibodies and V that bind to PD-1 H It comprises or consists of a single domain, and optionally a half-life extending moiety.
[0020] As shown herein, the use of bispecific agents of the present invention provides certain benefits because the molecules are selectively targeted to tumor-specific cells, thus exerting selective effects on signal transduction and proliferation. For example, bispecific agents that bind both PD-1 and LAG-3 have beneficial properties compared to combination therapy in which PD-1 and LAG-3 monoclonal antibodies are administered separately. This is because the bispecific antibodies target cells that express both targets, i.e., PD-1 and LAG-3, on their surface. Thus, the use of bispecific molecules allows for better targeting of T cells with the most exhausted phenotype (expressing both PD-1 and LAG-3). On the other hand, combination therapy provides universal blockade of each target on cells that express either target. It is also known that blockade of PD-1 increases the expression of LAG-3. Thus, treatment with bispecific agents may be particularly useful for treating patients who do not respond to PD-1 blockade or who have become unresponsive to PD-1 blockade. The bispecific agents described herein are selective for the most dysfunctional tumor infiltrating lymphocytes (TILs). They may find use in reversing endogenous or acquired PD-1 resistance. The reduction of PD-1 blockade spares peripheral T cells and avoids overactivation of immunologically functional PD-1 positive cells, resulting in an improved safety profile. Thus, the bispecific agents provide improved targeting and activity specifically against double positive cells, i.e., cells that present both LAG-3 and PD-1 on their surface. Moreover, as shown herein, the molecules also have improved properties over larger bispecific antibody forms. Without wishing to be bound by theory, this effect may be due to the specific configuration of the molecules described herein, which provides a smaller size, greater flexibility, and more complete and powerful clustering (recruitment of LAG-3 and PD-1 at the cell surface). Thus, the smallest antigen-binding entity, V H The molecular form based on provides further advantages.
[0021] A preferred binding agent of the present invention comprises at least one V targeting LAG-3. H Single domain antibodies and at least one V targeting PD-1 H Including single domain antibodies: Compared to large bispecific monoclonal antibodies, this format has the advantage of lacking an Fc domain, where Fc-mediated clearance can limit therapeutic efficacy.
[0022] Accordingly, the present invention provides an isolated human heavy chain variable domain (V) that binds to human LAG-3, comprising a CDR3 sequence selected from SEQ ID NO: 3 or 7, or a sequence having at least 70%, 80% or 90% homology / identity thereto. H ) relating to single domain antibodies.
[0023] In one embodiment, the VL1 gene of claim 1 comprises a CDR1 as set forth in SEQ ID NO: 1 or a sequence having at least 70%, 80% or 90% homology / identity thereto, a CDR2 as set forth in SEQ ID NO: 2 or a sequence having at least 70%, 80% or 90% homology / identity thereto, and a CDR3 as set forth in SEQ ID NO: 3 or a sequence having at least 70%, 80% or 90% homology / identity thereto. H Single domain antibodies.
[0024] In one embodiment, V H The single domain antibody comprises a CDR1 as set forth in SEQ ID NO:5 or a sequence having at least 70%, 80% or 90% homology / identity thereto, a CDR2 as set forth in SEQ ID NO:6 or a sequence having at least 70%, 80% or 90% homology thereto, and a CDR3 as set forth in SEQ ID NO:7 or a sequence having at least 70%, 80% or 90% homology thereto.
[0025] In one embodiment, V H A single domain antibody comprises a sequence selected from SEQ ID NO: 4 or 8, or a sequence having at least 70%, 80% or 90% homology / identity thereto.
[0026] In another aspect, the invention relates to the use of an anti-LAG-3 single domain antibody or a binding agent comprising an anti-LAG-3 single domain antibody to modify or block the interaction of LAG-3 with galectin 3, resectin and / or α-synuclein, for example as described herein. Methods of modifying or blocking the interaction of LAG-3 with galectin 3, resectin and / or synuclein by administering an sdAb or binding agent of the invention are also within the scope of the invention.
[0027] In another aspect, the invention relates to the treatment of a neurological condition comprising the administration of an anti-LAG-3 single domain antibody or a binding agent comprising an anti-LAG-3 single domain antibody, eg, as described herein. [Brief description of the drawings]
[0028] The present disclosure is further illustrated by the following non-limiting figures. [Figure 1] Bispecific binders containing VH sdAbs can bind targets simultaneously. LAG3-Fc was immobilized via amine coupling to an Octet® biosensor. Bispecific binder (i.e. binding to LAG-3 and PD-1) 1.1-6GS-1.1-6GS-2.63 was added at 100 nM, followed by PD-1-Fc. The profile shows binding of the bispecific (dark grey) to LAG-3, followed by additional binding of PD-1. LAG-3 specific (bivalent 1.1-6GS-1.1) shows binding to LAG-3, but as expected, addition of PD-1 shows no further binding (medium grey curve). [Diagram 2]CD4+ T cells were stimulated with anti-CD3 and anti-CD28. Cells were stained with HIS-tagged VH + anti-HIS tag labeled with biotin and streptavidin AlexaFluor488. Cells were analyzed using an Intellicyte® cytometer. The bispecific (i.e. binding to LAG-3 and PD-1) binder 1.1-6GS-1.1-9GS-2.63 binds with a higher median fluorescence than the individual components. The negative control is a VH that does not bind to the target. [Diagram 3]3a) Enhancement of IL-2 by combinations. Human PBMCs were stimulated with 10 ng / ml Staphylococcal Enterotoxin B (SEB) for 2 days. Cells were restimulated with 1 ng / ml SEB and 25 nM VH or full monoclonal antibodies (pembrolizumab and leratolimab analogs). When antibody combinations were used, equal concentrations were used, e.g. 25 nM PD-1 antibody (mAb) with 25 nM LAG-3 VH / antibody. After 3 days, culture supernatants were harvested for IL-2 measurement using an HTRF kit (Cisbio). 3b) Enhancement of IL-2 by bispecific molecules. Human PBMCs were stimulated with 10 ng / ml Staphylococcal Enterotoxin B (SEB) for 2 days. Cells were restimulated with 10 ng / ml SEB and titrations of VH or full monoclonal antibodies (nivolumab and leratolimab analogs). When antibody combinations were used, equal concentrations were used, e.g., 50 nM LAG3 antibody (mAb) with 50 nM PD-1 antibody (mAb). After 2 days, culture supernatants were harvested for IL-2 measurement using an HTRF kit (Cisbio). Negative control is a VH that does not bind to the target. 3c) Bispecific molecules induce more IL-2 than their constituent VHs. PBMCs were stimulated with 10 ng / ml SEB and restimulated with 0.1 ng / ml SEB in the presence of 50 nM or 50 + 50 nM VH for 3 days. 3d) In the context of bispecific molecules, bivalent LAG-3 single domain antibody constructs enhance IL-2 more potently than monovalent LAG-3. Human PBMCs were stimulated overnight with 50 ng / ml Staphylococcal Enterotoxin B (SEB). Cells were restimulated with 40ng / ml SEB and a titration of VH bispecifics (i.e. binding to LAG-3 and PD-1) for 2 days. 3e) IL-2 is enhanced more strongly in asymmetric forms than in some 1:1 forms. Human PBMCs were stimulated overnight with 20ng / ml Staphylococcal Enterotoxin B (SEB). Cells were restimulated for 3 days with 5ng / ml SEB and 10nM VH. 3f) Inflammatory cytokines are induced by bispecific molecules. Human PBMCs were stimulated overnight with 10ng / ml SEB. Cells were restimulated for 3-6 days with 1ng / ml SEB and 50nM VH. Supernatants were tested using the HTRF kit. [Figure 4] Proliferation of CMV-specific CD8+ T cells is enhanced by bispecific 1.1-6GS-1.1-9GS-2.63. PBMCs from eight donors were pulsed with 100 μM CMV peptide for 1 h. VHs were added to the cells at 100 nM and cultured for 5 days. The percentage of CD8+ T cells that were positive for seven different HLA tetramers was analyzed according to HLA typing. The fold increase over irrelevant VH was calculated. Each point represents one donor and one tetramer. Statistical significance was calculated using one way ANOVA and Dunns multiple comparison test. p=0.0002. [Diagram 5] The bispecific (i.e., binding to LAG-3 and PD-1) binder 1.1-6GS-1.1-6GS-2.77 with 10 mg / kg anti-mouse serum albumin (MSA) VH reduces tumor growth rate of RKO colon cancer cells when compared to control VH. Mean tumor volume at this time point (n=6 animals / group). Statistical significance was determined using two-way ANOVA with Tukey's post-hoc test (**p<0.01, ****p<0.0001). Negative control is a VH that does not bind to the target. [Figure 6] Patient T cell proliferation is enhanced by the bispecific and barely increased by PD-1 antibodies. Patient CD4+ or CD8+ T cells were incubated with tumor cell lines and the percentage of Ki67-positive cells was measured by flow cytometry. Detailed Description of the Invention
[0029] The present disclosure will now be further described. In the following sections, different aspects of the present disclosure are defined in more detail. Each aspect so defined can be combined with any other aspect or aspects, unless it is clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous can be combined with any other feature or features indicated as being preferred or advantageous.
[0030] Generally, the terminology and techniques used in the cell and tissue culture, pathology, oncology, molecular biology, immunology, microbiology, genetics, protein and nucleic acid chemistry, and hybridization described herein are well known and generally known in the art.The methods and techniques of the present disclosure are generally carried out according to conventional methods well known in the art, and as described in various general and more specific references cited and discussed throughout this specification, unless otherwise indicated.See, for example, Green and Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012); Therapeutic Monoclonal Antibodies: From Bench to Clinic, Zhiqiang An (Editor), Wiley, (2009); and Antibody Engineering, 2nd Ed., Vols. 1 and 2, Ontermann and Duebel, eds., Springer-Verlag, Heidelberg (2010).
[0031] Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclature used in analytical chemistry, organic synthetic chemistry, and medicinal and pharmaceutical chemistry described herein, and the experimental procedures and techniques thereof, are well known and commonly used in the art. Standard techniques are used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and patient treatment.
[0032] The present inventors have generated binding agents that are capable of specifically binding to the human LAG-3 antigen and that have several advantageous properties. These binding agents contain at least one V that binds to human LAG-3. HThe present invention comprises or consists of a single domain antibody. The present inventors have generated human heavy chain-only antibodies in transgenic mice expressing transgenes with human V, D and J regions and unable to produce functional endogenous heavy chains and kappa and lambda light chains. In the absence of light chains, heavy chain-only antibodies are generated in mice and undergo the normal process of somatic hypermutation and affinity maturation.
[0033] Thus, in accordance with the present invention, there is provided a method for the treatment of VLGA-3, which binds to human LAG-3 and blocks the interaction of LAG-3 with its ligands. H Provided are isolated binding molecules comprising at least one single domain antibody, such as single domain antibodies, pharmaceutical compositions comprising such binding molecules, as well as isolated nucleic acids, isolated recombinant expression vectors, and isolated host cells for making such binding proteins. For example, single domain antibodies are antibodies in which the domain is a human variable heavy chain (V H ) domain.
[0034] In one embodiment, the binding molecule comprises two or more V H Single domain antibodies, including at least one V H The single domain antibodies bind to human LAG-3. In one embodiment, the binding molecules each comprise a V H In one embodiment, the binding molecule comprises a single domain antibody and does not contain an additional entity that binds to LAG-3. H In one embodiment, the binding molecule comprises one or more V domains each of which binds to human LAG-3. H Single domain antibodies and V that bind to another target, e.g., PD-1 H Includes single domain antibodies.
[0035] Methods of using the binding molecules and single domain antibodies of the invention to detect human LAG-3, methods of treating disease, and methods of producing the binding molecules are also provided.
[0036] In one embodiment, the present invention provides one or more V H Single domain antibodies, e.g., two V H V containing single domain antibodies H For single domain antibodies or binding molecules, one and / or more V H Single domain antibodies exhibit one or more or all of the following properties, including combinations thereof: a) binds to human LAG-3; b) binds to monkey LAG-3; c) does not bind to mouse LAG-3; d) binds within the N-terminal domain of LAG-3; e) blocking LAG-3 binding to major histocompatibility complex (MHC) class II and restoring T cell signaling in reporter cell lines; f) blocks the binding of LAG-3 to human galectin-3 (Genbank accession BAA22164); g) blocks the binding of LAG-3 to human resectin (Genbank accession NP_940894); h) blocking the binding of LAG-3 to human α-synuclein (Genbank accession P37840); and / or j) Stimulating interleukin-2 (IL-2) production in T cells stimulated with superantigen and PD-1 blockade, see Example 10.
[0037] Suitable assays for measuring the above properties are described in the Examples and alternative methods will be known to those skilled in the art.
[0038] For example, according to the present invention, cells expressing MHC class II are inhibited from interacting with reporter T cells expressing LAG-3, resulting in increased NFAT-driven luciferase activity. H We demonstrated that single domain antibodies inhibit the interaction only at high concentrations (e.g., > 333 nM). H Single Domain Antibodies and Bispecifics HSingle domain antibodies (targeting both LAG-3 and PD-1) were shown to inhibit a dose-dependent increase in luciferase activity with EC50 values in the nanomolar range, e.g., from about 1.2 to about 8.3 nM.
[0039] For example, binding to human galectin-3 can be measured using an ELISA assay, with the sdAbs of the invention having IC50 values in the nanomolar range.
[0040] For example, binding to resectin can be measured using an ELISA assay, with the sdAbs of the invention having IC50 values in the nanomolar range.
[0041] For example, binding to α-synuclein can be measured using ELISA, and the sdAbs of the invention have IC50 values in the nanomolar range. H 1.1 inhibits the interaction between LAG-3 and α-synuclein with an IC50 of approximately 44.9 nM.
[0042] Stimulation of interleukin-2 (IL-2) production in superantigen-stimulated PBMCs can be assessed by measuring secreted IL-2 in HTRF as shown in the Examples. H Single domain antibodies show a 2-3 fold increase in IL-2 over PD-1 blockade alone.
[0043] In one embodiment, the present invention provides a single domain antibody, e.g., V, that binds to human LAG-3 and blocks the binding of LAG-3 to human galectin-3, resectin, and / or α-synuclein. H In some embodiments, the V H Single domain antibodies have the sequences described herein.
[0044] The above-mentioned properties of binding molecules and single domain antibodies can be utilized in the therapeutic and diagnostic methods and uses described herein.Such methods and uses are within the scope of the present invention.Compared to large monoclonal antibodies, the single domain form has an advantage by lacking Fc domain, since Fc-mediated clearance may limit therapeutic effect.Similarly, due to its small size, it can easily access its target, i.e., LAG-3.This is particularly beneficial for this target due to its expression in immune synapse.
[0045] In particular, as described below, the single domain antibodies that bind human LAG-3 described herein can be used in a multivalent and / or multispecific format, thus providing building blocks for the construction of multifunctional molecules.
[0046] The molecules described herein specifically bind to wild-type human LAG-3 (Accession No. NM_002286). The amino acid sequence of wild-type human LAG-3 is shown below (SEQ ID NO: 9). MWEAQFLGLLFLQPLWVAPVKPLQPGAEVPVVWAQEGAPAQLPCSPTIPLQDLSLLRRAGVTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPRRYTVLSVGPGGLRSGRLPLQPRVQLDERGRQRGD FSLWLRPARRADAGEYRAAVHLRDRALSCRLRLRLGQASMTASPPGSLRASDWVILNCSFSRPDRPASVHWFRNRGQGRVPVRESPHHHLAESFLFLPQVSPMDSGPWGCILTYRDGFNVSIMYNLTVLGL EPPTPLTVYAGAGSRVGLPCRLPAGVGTRSFLTAKWTPPGGGPDLLVTGDNGDFTLRLEDVSQAQAGTYTCHIHLQEQQLNATVTLAITVTPKSFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSF SGPWLEAQEAQLLSQPWQCQLYQGERLLGAAVYFTELSSPGAQRSGRAPGALPAGHLLLFLILGVLSLLLLVTGAFGFHLWRRQWRPRRFSALEQGIHPPQAQSKIEELEQEPEPEPEPEPEPEPEPEPEQL
[0047] The terms "LAG-3, LAG3, lymphocyte activation gene 3" and "CD223" are used interchangeably herein and include variants, isoforms, and species homologs of human LAG-3.
[0048] Unless otherwise specified, the term LAG-3 as used herein refers to human LAG-3. Thus, a single domain antibody described as binding to LAG-3 binds to human LAG-3.
[0049] "LAG-3 binding molecule / protein / polypeptide / agent", "LAG-3 antigen binding molecule protein / polypeptide / agent", "anti-LAG-3 single domain antibody", "anti-LAG-3 single immunoglobulin variable domain", "anti-LAG-3 heavy chain only antibody", "anti-LAG-3 V H Single domain antibody, anti-LAG-3 V HThe terms "antibody" or "anti-LAG-3 antibody" all refer to a molecule capable of specifically binding to the human LAG-3 antigen as described above. Binding reactions can be demonstrated by standard methods, for example with reference to a negative control test using an antibody of irrelevant specificity. The terms "binding agent" and "binding molecule" are used interchangeably herein. The terms binding molecule and binding agent all refer to a biological entity, e.g. a protein such as a fusion protein, that can specifically bind to the human LAG-3 antigen as described above.
[0050] A single domain antibody or binding molecule comprising a single domain antibody as described herein that "binds" or is "capable of binding" to an antigen of interest, e.g., human LAG-3, is one that binds to the antigen with sufficient affinity such that the antibody is useful as a therapeutic agent in cells or tissues expressing the antigen.
[0051] The single domain antibodies or binding molecules comprising single domain antibodies described herein do not cross-react with mouse LAG-3.
[0052] In one embodiment, the single domain antibodies described herein bind to human LAG-3 and also bind to cynomolgus monkey LAG-3.
[0053] The single domain antibodies and binding agents described herein that bind to LAG-3 are also referred to herein as "blocking single domain antibodies or antibodies" or "neutralizing single domain antibodies or antibodies," and refer to single domain antibodies or binding agents that inhibit at least one biological activity of LAG-3 by binding to LAG-3. For example, said biological activity of LAG-3 is selected from one or more of the following: a) Interaction with MHC class II; b) interaction with galectin-3; c) interaction with resectin; d) ligand-mediated signaling in cells expressing LAG-3; e) Effects on the T cell receptor signaling pathway; f) LAG-3 oligomerization or interaction with other cell surface receptors in the immune synapse; g) binding of soluble LAG-3 cleaved from the cell surface; and / or h) Regulation of T regulatory cells.
[0054] As used herein, the terms "specific binding" or "specifically binds" or "specific for" a particular polypeptide or epitope on a particular polypeptide target means, for example, at least about 10 -4 M, or at least about 10 -5 M, or at least about 10 -6 M, or at least about 10 -7 M, or at least about 10 -8 M, or at least about 10 -9 M, or at least about 10 -10 M, or at least about 10 -11 M, or at least about 10 -12 M, or greater. In one embodiment, the term "specific binding" refers to binding by a molecule to a particular polypeptide or epitope on a particular polypeptide without substantial binding to other polypeptides or polypeptide epitopes.
[0055] In one embodiment, the monovalent single domain antibody described herein comprises 10 -9 At least 10 -5 In another embodiment, the bivalent single domain antibody described herein has a KD of up to 10 -9 ~10 -12 Has KD of M or higher.
[0056] The term "antibody" refers broadly to an immunoglobulin (Ig) molecule, which is composed of four polypeptide chains, two heavy (H) chains and two light (L) chains, or an antigen-binding portion thereof, or any functional fragment, mutant, variant, or derivative thereof that retains the essential epitope-binding properties of an Ig molecule. Such mutant, variant, or derivative antibody forms are known in the art.
[0057] In full-length antibodies, each heavy chain is composed of a heavy chain variable region or domain (abbreviated herein as HCVR) and a heavy chain constant region. The heavy chain constant region is made up of three domains, C H 1. C H 2 and C H Each light chain is composed of a light chain variable region or domain (abbreviated herein as LCVR) and a light chain constant region. The light chain constant region is made up of one domain, C L It is composed of:
[0058] The heavy and light chain variable regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs). Each heavy and light chain variable region is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0059] The immunoglobulin molecule can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.
[0060] The term "CDR" refers to the complementarity determining region in the antibody variable sequence. There are three CDRs in each of the heavy and light chain variable regions, which are called CDR1, CDR2 and CDR3 for each variable region. The term "CDR set" refers to a group of three CDRs that occur in a single variable region that can bind to antigen. The exact boundaries of these CDRs can be defined in various ways according to various systems known in the art.
[0061] The Kabat complementarity determining regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., (1971) Ann. NY Acad. Sci. 190:382-391 and Kabat, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). Chothia refers instead to the location of the structural loops (Chothia and Lesk J. Mol. Biol. 196:901 -917 (1987)). When referring to residues in the variable domain (approximately residues 1-107 in the light chain and residues 1-113 in the heavy chain), the Kabat numbering system is commonly used.
[0062] The Kabat system is used herein unless otherwise specified. The terms "Kabat numbering", "Kabat definition" and "Kabat labeling" are used interchangeably herein. These art-recognized terms refer to a system of numbering amino acid residues that are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody or antigen-binding portion.
[0063] A chimeric antibody is a recombinant protein that contains the variable domains, including the complementarity determining regions (CDRs), of an antibody derived from one species, preferably a rodent antibody, and the constant domains of the antibody molecule are derived from the constant domains of a human antibody. For veterinary applications, the constant domains of the chimeric antibody may be derived from the constant domains of other species, such as cats or dogs.
[0064] A humanized antibody is a recombinant protein in which the CDRs of a certain antibody, e.g., a rodent antibody, are transferred from the heavy and light variable chains of the rodent antibody to human heavy and light variable domains (e.g., framework region sequences). The constant domains of the antibody molecule are derived from the constant domains of a human antibody. In certain embodiments, a limited number of framework region amino acid residues from the parent (rodent) antibody can be replaced with human antibody framework region sequences.
[0065] The term "antigen-binding site" refers to the portion of an antibody or antibody fragment that comprises the area that specifically binds to an antigen. An antigen-binding site may be provided by one or more antibody variable domains. Preferably, an antigen-binding site is provided by the associated V domains of an antibody or antibody fragment. H and V L Included within.
[0066] An antibody fragment is a portion of an antibody, such as F(ab')2, Fab, Fv, sFv, etc. A functional fragment of a full-length antibody retains the target specificity of the full-length antibody. Thus, recombinant functional antibody fragments such as Fab (fragment antibody), scFv (single-chain variable fragment) and single domain antibodies (dAb) have been used to develop therapeutics as an alternative to mAb-based therapeutics.
[0067] The scFv fragment (~25 kDa) contains two variable domains, V H and V L Of course, V H and V LThe domains tend to associate and dissociate non-covalently through hydrophobic interactions, however stable fragments can be engineered by crosslinking the domains with hydrophilic flexible linkers to create single-chain Fvs (scFvs).
[0068] The smallest antigen-binding fragment is a single variable fragment, i.e., V H or V L The binding of each light / heavy chain partner is not required for target binding. Such fragments are called single domain antibodies. Thus, single domain antibodies (~12-15 kDa) have V H or V L domain and does not include other parts of an antibody. H and V L Each domain can bind to an antigen. H or V L Antigen-binding entities of antibodies that are reduced to a single domain (corresponding to a single variable domain) are commonly referred to as "single domain antibodies" or "immunoglobulin single variable domains". Single domain antibodies derived from camelid heavy chain-only antibodies that are naturally devoid of light chains, as well as single domain antibodies with human heavy chain domains have been described (Muyldermans J Biotechnol. 2001 Jun;74(4):277-302, Holliger Nat Biotechnol. 2005 Sep;23(9):1126-36).
[0069] Antigen-binding single V H The domains are, for example, mouse V H It was also identified from a gene library and expressed in E. coli (Ward et al., 1989, Nature 341: 544-546). H The domains were named "dAbs", or "domain antibodies". The term "dAb" generally refers to a single immunoglobulin variable domain (V) that specifically binds an antigen. H , V HH or VL ) polypeptides. Camelid-derived V-cells are preferred for therapeutic use, primarily because they are less likely to elicit an immune response when administered to patients. HH Human single domain antibodies are preferred.
[0070] The terms "single domain antibody (sdAb), variable single domain or immunoglobulin single variable domain (ISV)" are all well known in the art and refer to a single variable fragment of an antibody that binds to a target antigen. These terms are used interchangeably herein. "Single heavy domain antibody, single variable heavy domain, immunoglobulin single heavy variable domain (ISV), human V H Single domain, V H "Single domain antibody" refers to an isolated single heavy chain variable fragment of an antibody that retains the binding specificity with an antigen in the absence of light chains or other antibody fragments. Thus, a single domain antibody does not contain other portions of an intact antibody molecule. A single variable heavy chain domain antibody can bind to an antigen even in the absence of a light chain. Human heavy chain single variable domain antibodies (V H Domain antibodies) are preferred.
[0071] In one aspect, we provide an isolated single variable heavy domain antibody that binds to human LAG-3.
[0072] As described below, certain embodiments relate to isolated single variable heavy domain antibodies / immunoglobulin single variable heavy domains that bind to the LAG-3 antigen. Thus, single variable heavy domain antibodies are capable of binding to LAG-3 in the absence of light chains. Human single variable heavy domain antibodies ("VHDAs") are also known. H Particularly preferred are "single domain antibodies" (Humabodies). Such binding molecules are also referred to herein as Humabodies®. Humabody® is a registered trademark of Crescendo Biologics Ltd.
[0073] In some embodiments, we provide isolated binding agents / molecules comprising or consisting of at least one single domain antibody, said domains being human variable heavy chain domains; L It lacks a domain or other antibody fragment that binds to the target antigen.
[0074] The term "isolated" single domain antibody refers to a single domain antibody that is substantially free of other single domain antibodies, antibodies or antibody fragments with different antigen specificity. Furthermore, an isolated single domain antibody may be substantially free of other cellular material and / or chemicals. The sdAbs of the present invention and binding molecules comprising such sdAbs are preferably derived / isolated from heavy chain-only antibody isolated transgenic mice expressing a transgene with human V, D and J regions and producing heavy chain-only antibodies. This is explained in detail in the Examples.
[0075] Each single V H A domain antibody is composed of three CDRs and four FRs, arranged from amino terminus to carboxy terminus in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Thus, in one embodiment, the domain comprises a human variable heavy chain (VH) having the following formula: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. H ) domain.
[0076] C- or N-terminal V H Modifications to the framework sequences may be made to the single domain antibodies of the invention to improve their properties. For example, V H The domains may contain C-terminal or N-terminal extensions or deletions. The C-terminal extension is a V H It may be added to the C-terminus of the domain.
[0077] In one embodiment, the single domain antibody described herein comprises a C-terminal extension of 1 to 50 residues, such as 1 to 10, 1 to 20, 1 to 30, 1 to 40, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 additional amino acids. H 1 domain of additional amino acids, and thus the C-terminus is C H In one embodiment, the extension comprises at least one alanine residue, such as a single alanine residue, two alanine residues or three alanine residues.
[0078] In another embodiment, the additional residues at the C-terminus or N-terminus are selected from a linker used to conjugate the single domain antibodies described herein to another moiety, such as a peptide linker or a tag that aids in detection of the molecule. Such tags are well known in the art and include, for example, linker His tags, such as hexaHis or myc tags.
[0079] As used herein, the term "homology" or "identity" generally refers to the percentage of amino acid residues in a sequence that are identical to the residues of the compared reference polypeptide, after aligning the sequences and, in some embodiments, introducing gaps, if necessary, to maximize the percentage of homology, without considering conservative substitutions as part of the sequence identity. Thus, the percentage of homology between two amino acid sequences is equal to the percentage of identity between the two sequences. N- or C-terminal extensions, tags, or insertions should not be construed as reducing the identity or homology. Methods and computer programs for alignment, such as Blast, are well known. The percentage of homology or identity between two amino acid sequences can be determined using well-known mathematical algorithms. When homology is used herein, it can be replaced with identity.
[0080] According to some embodiments of the various aspects described herein, the variable domain of the single domain antibody described herein is H Domain, V HH Domain, humanized V HH Domain, Camelization V H Domain, sequence modification V H or V HH In a preferred embodiment, the variable domains of the single domain antibodies described herein are human variable domains (V H The term "V H ", e.g., V as used herein H A domain antibody refers to a single human variable heavy chain domain antibody.
[0081] As used herein, human V H The domain contains a fully human V H Domain or substantially completely human V H As used herein, human V H The term domain refers in particular to a V domain isolated from a heavy chain-only antibody generated by a transgenic mouse expressing a fully human immunoglobulin heavy chain locus in response to immunization with a desired antigen, as described, for example, in WO2016 / 062990 and in the Examples. H In one embodiment, the human V H Domain: Human V H Amino acids of domains or such V H V derived from or based on a nucleic acid sequence encoding a domain H The term may also include variable heavy chain regions derived from or encoded by human germline immunoglobulin sequences. H Domain, or human V H V derived from or based on the domain HA domain may contain amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced in vitro by random or site-directed mutagenesis, or by somatic mutation in vivo). Thus, a "human V domain" may be used. H The term "domain" refers to a substantially human V domain in which one or more amino acid residues have been modified, e.g., to correct a sequence defect. H domains, such as substantially human V H A domain may contain up to 20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications compared to the entire human sequence.
[0082] However, as used herein, "human V H Domain" or "Substantially Human V H The term "human V domain" is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. H The term "domain" refers to the camelized V H Domains, i.e., for example, V H One or more predetermined residues of the Camelidae V domain are selected in vitro by conventional mutagenesis techniques, in which a predetermined position in the domain is selected and one or more point mutations are introduced at the predetermined position. HH Human V modified at specific residues found in the domain H Not intended to include domains.
[0083] Exemplary Sequence Properties In one embodiment, a single V polypeptide that binds to human LAG-3 is HThe domain antibody comprises a CDR3 sequence as shown in Table 1 below, or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence homology or identity thereto. Thus, in one embodiment, the inventors have provided an isolated single V domain antibody comprising a CDR3 sequence selected from SEQ ID NO: 3 or 7, or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence homology or identity thereto, capable of binding to human LAG-3. H Domain antibodies are described. In one embodiment, the sequence identity is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In one embodiment, the sequence identity is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
[0084] In one embodiment, a single V H The domain antibody comprises a CDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 5, or a sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%96%, 97%, 98% or 99% homology or identity thereto. HThe domain antibody further comprises a CDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 2 or 6, or a sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%96%, 97%, 98% or 99% homology or identity thereto.
[0085] In one embodiment, V H A single domain antibody comprises a CDR1 comprising SEQ ID NO:1 or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto, a CDR2 comprising SEQ ID NO:2 or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto, and a CDR3 comprising SEQ ID NO:3 or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. H A single domain antibody comprises a CDR1 comprising SEQ ID NO:5 or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto, a CDR2 comprising SEQ ID NO:6 or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence identity or identity thereto, and a CDR3 comprising SEQ ID NO:7 or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto.
[0086] In one embodiment, V HA single domain antibody comprises or consists of SEQ ID NO:4 or SEQ ID NO:8, or a sequence having at least 60%, 70%, 80%, 90%, 95% or more sequence homology thereto, for example 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%96%, 97%, 98% or 99% homology or identity thereto.
[0087] [Table 1]
[0088] In some embodiments, the inventors have identified a single V H Any variant of the domain antibody V H Single domain antibodies are provided.
[0089] Mutant V used in the present invention H Single domain antibodies have one or more amino acid substitutions, deletions, insertions or other modifications and retain the functional properties described herein. For example, the mutant V that binds to LAG-3 H For single domain antibodies, the functional property may be binding to LAG-3 or one of the other properties listed above.
[0090] Mutation V H Single domain antibodies can be modified in sequence. Modifications include those that modify the native sequence V HThese include one or more substitutions, deletions or insertions of one or more codons encoding the single domain antibody or polypeptide resulting in a change in the amino acid sequence compared to the single domain antibody or polypeptide. The amino acid substitution can be the result of replacing one amino acid with another amino acid having similar structural and / or chemical properties, such as a leucine for a serine, i.e., a conservative amino acid substitution. The insertions, substitutions or deletions can be anywhere from 1 to 20 amino acids, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or in the range of 1 to 10 amino acids. In one embodiment, the variants have 1, 2, 3, 4 or 5 substitutions. Tolerated mutations can be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
[0091] In one embodiment, the modification is a conservative sequence modification. As used herein, the term "conservative sequence modification" refers to an amino acid modification that does not significantly affect or change the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into a single domain by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR regions of the single domain antibodies described herein can be substituted with other amino acid residues from the same side chain family, and the modified antibodies can be tested for retained function (i.e., the functions described in (c)-(l) above) using the functional assays described herein.
[0092] Thus, these amino acid changes can typically be made without changing other desired properties of the polypeptide, such as biological activity, function, or affinity or specificity for antigens. In general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially change biological activity. Furthermore, substitutions of amino acids with similar structures or functions are unlikely to inhibit biological activity of the polypeptide. The abbreviations of amino acid residues that comprise the polypeptides and peptides described herein, and conservative substitutions of these amino acid residues are shown in Table 2 below.
[0093] [Table 2]
[0094] In some embodiments, the inventors have provided a variant of a single domain antibody V that binds to LAG-3 selected from those shown in Table 1 and that comprises one or more sequence modifications and has one or more improved properties, such as binding affinity, specificity, thermal stability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility, compared to an unmodified single domain antibody. H Single domain antibodies are provided.
[0095] Those skilled in the art will know that there are different methods for identifying, obtaining and optimizing the antigen-binding molecules described herein, including in vitro and in vivo expression libraries. This is further described in the examples. Optimization techniques known in the art, such as display (e.g., ribosome and / or phage display) and / or mutagenesis (e.g., error-prone mutagenesis), can be used. Thus, the inventors also provide sequence-optimized variants of the single domain antibodies described herein.
[0096] In one embodiment, modifications can be made to reduce the immunogenicity of single domain antibodies. For example, one approach is to return one or more framework residues to the corresponding human germline sequence. More specifically, a single domain antibody that has undergone somatic mutation may contain framework residues that differ from the germline sequence from which the single domain antibody is derived. Such residues can be identified by comparing the framework sequence of the single domain antibody with the germline sequence from which the single domain antibody is derived. To return one or more amino acid residues of the sequences of the framework region to their germline configuration, the somatic mutations can be "backmutated" to the germline sequence, for example, by site-directed mutagenesis or PCR-mediated mutagenesis.
[0097] Another type of framework modification involves mutating one or more residues within the framework regions, or within one or more CDR regions, to remove T-cell epitopes, thereby reducing the potential immunogenicity of the antibody.
[0098] In yet another embodiment, the glycosylation of the molecule is modified. Glycosylation can be altered to, for example, increase the affinity of the molecule to an antigen. Such carbohydrate modification can be achieved, for example, by modifying one or more glycosylation sites in the molecule sequence. For example, one or more amino acid substitutions can be made to remove one or more variable region framework glycosylation sites, thereby removing glycosylation at that site. Such deglycosylation can increase the affinity of the molecule to an antigen.
[0099] In one embodiment, V H The single domain antibody has a CDR1 as shown in SEQ ID NO: 1 or SEQ ID NO: 1 with 1 to 5 amino acid substitutions, a CDR2 as shown in SEQ ID NO: 2 or SEQ ID NO: 2 with 1 to 5 amino acid substitutions, and a CDR3 as shown in SEQ ID NO: 3 or SEQ ID NO: 3 with 1 to 5 amino acid substitutions. HThe single domain antibody has a CDR1 shown in SEQ ID NO:5 or SEQ ID NO:1 having 1 to 5 amino acid substitutions, a CDR2 shown in SEQ ID NO:5 or SEQ ID NO:2 having 1 to 5 amino acid substitutions, and a CDR3 shown in SEQ ID NO:7 or SEQ ID NO:3 having 1 to 5 amino acid substitutions.
[0100] In one embodiment, variant V H Single domain antibodies are selected from any one of SEQ ID NOs: 4 or 8, but containing one or more amino acid substitutions, for example 1 to 20, for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. In one embodiment the variant has 1, 2, 3, 4 or 5 substitutions.
[0101] In one embodiment, V H The single domain antibody is represented by SEQ ID NO:4 (V H 1.1) but with amino acid substitutions at one or more of the following positions: S23, P119, N57, S58, N54, D30, Y32, S58, G55, G56, N57, G59, Y95, S106, S108 and / or A107. In one embodiment, two or more substitutions at these 16 positions are combined, for example, the variant may include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 substitutions, the positions of which are selected from those listed above. In one embodiment, the variant includes a substitution at S23 and one or more substitutions from those listed above.
[0102] In one embodiment, one or more of the following amino acid substitutions are selected from S23A, P119Q, N57S, S58T, N54I, D30N, Y32F, S58T, G55S, G56D, N57I, N57S, S58T, G59A, Y95H, S106V, S108A and / or A107T. In one embodiment, the variant comprises a substitution at S23A and one or more substitutions from the above.
[0103] In one embodiment, the substitution is S23A (Mutant 1). In one embodiment, the substitution is S23A, P119Q, N57S and S58T (Mutant 2, V H 1.2). In one embodiment the substitutions are S23A, N57S and S58T (mutant 3). In one embodiment the substitutions are S23A and N54I (mutant 4). In one embodiment the substitutions are S23A, D30N, Y32F and S58T (mutant 5). In one embodiment the substitutions are S23A, Y32F, G55S, G56D, N57I, S58T and G59A (mutant 6). In one embodiment the substitutions are S23A, Y32F, S58T, S106V and S108A (mutant 7). In one embodiment the substitutions are S23A, D30N and A107T (mutant 8). In one embodiment the substitutions are S23A, Y95H, G56D, N57S and S58T (mutant 9).
[0104] All of the above mutants were tested for binding to LAG-3 and exhibited a KD in the nanomolar range.
[0105] [Table 3]
[0106] The numbering above is based on the position of the residues in the protein as depicted herein.
[0107] The V H Single domain antibodies exhibit excellent stability. They have been shown to be resistant to heat stress at high concentrations. Furthermore, the V H The single domain antibodies also demonstrate specificity for human LAG-3, binding to human T cells, blocking LAG-3 ligand binding and stimulation of T cell activity (see Examples).
[0108] V that binds to LAG-3 as described herein HSingle domain antibodies preferably have a K value as further described herein and shown in the Examples, e.g., a K value of at least about 10 as measured by biolayer interferometry (Biomolecular Interaction Analysis, Octet®). -8 It can be M.
[0109] The term "KD" refers to the "equilibrium dissociation constant", which is the value obtained in a titration measurement at equilibrium or the value obtained by dividing the dissociation rate constant (Koff) by the association rate constant (Kon). "KA" refers to the affinity constant. The association rate constant, dissociation rate constant, and equilibrium dissociation constant are used to describe the binding affinity of an antibody to an antigen. Methods for determining association and dissociation rate constants are well known in the art. By using fluorescence-based techniques, samples in physiological buffer at equilibrium can be tested with high sensitivity. Other experimental approaches and instruments such as HTRF, flow cytometry, fluorescence microvolume assay techniques can be used. In some embodiments, the binding molecule can bind to LAG-3 with a KD value of up to about 6.15 μM or less, for example, about 50 nM, about 10 nM, or about 5 nM or less, when the fusion polypeptide is measured using biolayer interferometry (Octet®), for example, essentially as described in Example 8.
[0110] The binding molecule may bind to LAG-3 with an EC50 value of up to 100 nM or less, e.g., about 10 nM, about 5 nM or about 2 nM or less, when the fusion polypeptide is measured in an HTRF binding assay, e.g., as described in Example 8.
[0111] In one embodiment, the V H Single domain antibodies may be prepared using human V domain antibodies as further described herein. H V that binds to LAG-3, or obtained from transgenic mice expressing the gene H A sequence-optimized variant of a single domain antibody.
[0112] The present disclosure further provides isolated nucleic acids encoding single domain antibodies that bind to LAG-3 as described herein. The nucleic acids may comprise DNA and / or RNA. In one embodiment, the inventors have isolated nucleic acids encoding single domain antibodies that bind to LAG-3 as described herein. The nucleic acids may comprise DNA and / or RNA. In one embodiment, the inventors have isolated nucleic acids encoding single domain antibodies that bind to LAG-3 as described herein. H Nucleic acids encoding single domain antibodies are provided.
[0113] Nucleic acid sequence In one embodiment, we provide an isolated nucleic acid sequence comprising or consisting of a sequence selected from SEQ ID NO: 10 or 11 shown in Table 4. The nucleic acid sequence of Table 4 is selected from the V H Encoding a single domain antibody.
[0114] In one embodiment, the nucleic acid sequence has at least 60%, 70%, 80%, 90%, 95% or more sequence homology or identity to one of the sequences selected from Table 2. In one embodiment, the sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment the nucleic acid sequence, the nucleic acid sequence has 1 to 20 substitutions compared to SEQ ID NO: 10 or 11.
[0115] [Table 4]
[0116] The nucleic acids of the invention may comprise DNA or RNA and may be wholly or partially synthetically or recombinantly produced. Reference to a nucleotide sequence described herein includes DNA molecules having the particular sequence, unless the context otherwise requires, and includes RNA molecules having the particular sequence in which U is substituted for T. Variants of the nucleic acids set forth above, such as variants having up to 20 codon changes, particularly the V and VV sequences provided herein, may also be used. H Encoding variants (see Table 3) are also within the scope of the invention.
[0117] Furthermore, the present inventors provide an isolated nucleic acid construct comprising at least one nucleic acid as defined above. The construct may be in the form of a plasmid, vector, transcription or expression cassette.
[0118] The present invention also relates to an isolated recombinant host cell comprising one or more of the above nucleic acid constructs. The host cell can be a bacterial, viral, plant, fungal, mammalian or other suitable host cell. In one embodiment, the cell is an E. coli cell. In another embodiment, the cell is a yeast cell. In another embodiment, the cell is a Chinese Hamster Ovary (CHO) cell, a HeLa cell, or other cell that will be apparent to one of skill in the art. In one embodiment, the host cell is a mammalian host cell, but is not a human host cell.
[0119] In one embodiment, there is provided a method of making an anti-LAG-3 single domain antibody as described herein, the method comprising culturing a host cell under conditions suitable for expression of a polynucleotide encoding the single domain antibody, and isolating the single domain antibody.
[0120] Agents that compete with the molecule for binding to human LAG-3 In another aspect, the inventors provide binding molecules, e.g., antibodies, antibody fragments or antibody mimetics, that bind to an epitope on human LAG-3 in a manner similar to any of the LAG-3 single domain antibodies of the invention (i.e., antibodies that have the ability to cross-compete with any of the single domain antibodies for binding to human LAG-3; thus, single domain antibodies can be used as reference antibodies). In some embodiments, the reference antibody for cross-competition studies is the single domain antibody V shown herein. H 1.1 (see Table 1).
[0121] Such cross-competing antibodies can be identified based on their ability to cross-compete with single domain antibody 1.1 or 1.2 for binding to human LAG-3 in standard binding assays. For example, BIAcore® analysis, ELISA assays or flow cytometry can be used to demonstrate cross-competition with the single domain antibodies of the invention.
[0122] In one embodiment, we provide a binding agent capable of binding human LAG-3, where the single domain antibody described above displaces the binding agent in a competitive assay. In some embodiments, the binding agent is an antibody, a functional fragment thereof, such as a single domain antibody, or an antibody mimetic protein. In another aspect, we provide a binding agent capable of binding human LAG-3, where the binding agent displaces the single domain antibody described above in a competitive assay. In another aspect, we provide a binding agent capable of binding human LAG-3, where the binding agent binds to essentially the same epitope, including overlapping epitopes, as the single domain antibodies described herein.
[0123] In another embodiment, we provide a multivalent molecule, e.g. a bivalent molecule, or a combination of one or two of the above V H The above V for use in multispecific molecules including single domain antibodies H Single domain antibodies are provided.
[0124] Heavy chain only antibodies In another aspect, the present inventors have discovered that the V H The present invention provides isolated heavy chain-only antibodies comprising the domains or having at least 60%, 70%, 80%, 90% or 95% homology or identity thereto.
[0125] Multivalent Binders The single domain antibodies that bind to LAG-3 described herein may be administered in combination with another therapeutic agent, as further described below.
[0126] Furthermore, the single domain antibodies that bind LAG-3 described herein can form part of a multivalent binding agent / molecule. Such agents include a single domain antibody that binds LAG-3 and one or more subunits / moieties that bind one or more target antigens. In the multivalent binding agents described herein, at least two binding entities are covalently or non-covalently linked. For example, in the embodiments described below, the multispecific binding agent is preferably a fusion protein, and thus the present disclosure provides a fusion protein that includes a single domain antibody that binds LAG-3 described herein. Preferably, the fusion polypeptide is a translational fusion between two or more subunits. Techniques for generating translational fusions are well known and include genetically engineering the coding sequence of one subunit in a reading frame with the coding sequence of a further subunit. The two subunits are linked, for example, by a nucleic acid sequence that encodes a peptide linker. Exemplary peptide linkers are described in more detail below. In a preferred embodiment, the binding agent comprises or consists of two or three or more single domain antibodies, for example a fusion protein in which a single domain antibody is linked to another single domain antibody. As will be apparent to those skilled in the art, such proteins do not contain other portions of an entire antibody molecule, and binding to the target is mediated by the single domain antibody.
[0127] Thus, in another aspect, the present invention provides a VAG-3 binding polypeptide for use in the construction of multivalent and / or multifunctional fusion proteins. H Single domain antibodies (see, for example, the single domain antibodies or variants thereof shown in Table 1) are provided. Accordingly, another embodiment provides a V that binds LAG-3 as described herein in a multifunctional fusion protein. H Another embodiment relates to the use of a single domain antibody (e.g., having a sequence as shown in Table 1 or a variant thereof) that binds to LAG-3 linked to a second nucleic acid that encodes a protein that binds to a second therapeutic target in a host cell. H Also relates to a method of making a multivalent binding agent comprising expressing a nucleic acid construct comprising a nucleic acid encoding a single domain antibody (e.g., as shown in Table 4) and isolating said multifunctional protein from said host cell. Accordingly, further embodiments also relate to multivalent binding agents comprising a single domain antibody that binds to LAG-3 as described herein, e.g., as shown in Table 1.
[0128] Molecules that are composed of the LAG-3 binding components described herein can be designed for optimal target binding, for example, through linker design. This can lead to improved function or reduced dosage. In addition to the functional advantages described herein, the advantages of the above multifunctional molecules over molecular combinations include, but are not limited to, simpler routes through production, preclinical trials and clinical administration.
[0129] A multivalent binding agent is one that contains at least two moieties that have binding specificity for the same or different epitopes on the same or different targets. A "multispecific" binding agent is one that recognizes multiple epitopes on one or more antigens. A bispecific binding agent is one that recognizes two different epitopes on the same or different antigens.
[0130] Thus, one aspect relates to a multivalent binding agent comprising a single domain antibody that binds to LAG-3, e.g., one having the amino acids described herein, and one or more further moieties, e.g., a second sdAb. For example, the binding agent may be a bispecific binding agent, as described further below. In one embodiment, the second moiety binds to an antigen of therapeutic interest. In one embodiment, the second moiety is a binding molecule that binds to the antigen, e.g., an antibody or antibody fragment (e.g., Fab, F(ab')2, Fv, single chain Fv fragment (scFv) or a single domain antibody, e.g., V H In another embodiment, the single domain antibody described herein is a binding molecule selected from a C H 2 and C H In one preferred embodiment, the second moiety can be linked to an antibody Fc region or a fragment thereof, comprising one or both of the V3 domains and optionally a hinge region. H It is a domain antibody.
[0131] The binding agent may be multivalent, e.g., bivalent, or multiparatopic, e.g., biparatopic. Thus, in one embodiment, the binding molecule comprises a first V that binds to LAG-3. H Single Domain Antibody V H (A) and a second V that binds to LAG-3 or another target antigen H Single Domain Antibody V H (B) and thus has the formula: H (A)-LV H (B), where L is a linker, e.g., a peptide linker.
[0132] Each V H has CDR and FR regions. Thus, in one embodiment, the first V H Single Domain Antibody V H (A) and the second V H Single Domain Antibody V HA binding molecule having (B) has the formula: FR1(A)-CDR1(A)-FR2(A)-CDR2(A)-FR3(A)-CDR3(A)-FR4(A)-L-FR1(B)-CDR1(B)-FR2(B)-CDR2(B)-FR3(B)-CDR3(B)-FR4(B). The order of the immunoglobulin single variable domains A and B is not particularly limited, so that within the polypeptides described herein, the immunoglobulin single variable domain A may be positioned at the N-terminus and the immunoglobulin single variable domain B at the C-terminus, or vice versa. H Domain antibodies usually consist of a first V H The C-terminus of the second V H and the N-terminus of the
[0133] In one embodiment, the binding molecule is biparatopic. In one embodiment, the binding molecule is bivalent. In one embodiment, the binding molecule is multispecific, e.g., bispecific, trispecific, or tetraspecific.
[0134] Bivalent binding molecules The inventors surprisingly found two V that both bind to LAG-3 in a single molecule. H Combining single domain antibodies is beneficial, as is the monovalent V that binds LAG-3. H It was found that the effect was increased compared to single domain antibodies. As shown in the examples, H Bivalent molecules combining single domain antibodies bind LAG-3 with increased KD and produce monovalent LAG-3-binding V H The EC50 and IC50 values are increased compared to single domain antibodies. For example, monovalent LAG-3V H binds weakly to cells, whereas this is enhanced when in the form of a bivalent molecule (see FIG. 2, Example 8).
[0135] Thus, in one embodiment, the present invention provides two V HSingle domain antibodies, e.g., molecules, fusion proteins, constructs or combined molecules, comprising or consisting of two molecules of the same or different sequence, are provided. H Single domain antibodies may bind to the same epitope on LAG-3 or to different epitopes on LAG-3 (biparatopic). Such molecules that are bivalent for LAG-3 binding are H -LV H wherein L is a peptide linker and optionally V H -LV H -LX, where X is another linking moiety, e.g., another V H In another embodiment, the molecule is a single domain antibody. Thus, such a molecule contains only a single domain antibody, and no other portion of the antibody is present. Optionally, the molecule may contain an additional C-terminal portion, such as a half-life extension portion, and / or an additional amino acid sequence, such as a tag or amino acid sequence of up to 25 amino acids. As further described herein, L is a protein linker. In another embodiment, the molecule is a single domain antibody that binds to human LAG-3, selected from those shown in Table 1. H A bivalent construct, protein or binding molecule is provided that comprises or consists of a single domain antibody or variant thereof. In one embodiment, the two V H In another embodiment, the binding molecule binds to human LAG-3 and has two V domains with different sequences. H It may comprise a single domain antibody, each selected from the sequences shown in Table 1 or described herein or variants thereof. The molecule or construct is a fusion protein.
[0136] Thus, in various embodiments, the binding molecule comprises a first V H Single Domain Antibody V H (A) and the second V H Single Domain Antibody V H (A) or V H (A′) and therefore has the formula: V H (A)-LV H(A) or V H (A)-LV H (A'), where L is a linker, e.g., a peptide linker. H (A) and V H (A') Both bind to human LAG-3.
[0137] In one embodiment, the binding molecule is H V linked with 1.1 H 1.1. In one embodiment, the binding molecule comprises V H V linked with 1.2 H 1.2, i.e., the molecule contains V H 1.2-LV H 1.2. In one embodiment, the binding molecule can be written as V H V linked with 1.2 H Includes 1.1.
[0138] The bivalent binding molecules described herein can be constructed using methods known in the art and as described in the Examples.
[0139] In one embodiment, such a bivalent fusion protein comprises one of the following: SEQ ID NO:4-(G4S)n-SEQ ID NO:4, SEQ ID NO:8-(G4S)n-SEQ ID NO:8, SEQ ID NO:4-(G4S)n-SEQ ID NO:8, SEQ ID NO:8-(G4S)n-SEQ ID NO:4.
[0140] Another aspect relates to nucleic acid molecules encoding such fusion proteins.
[0141] In one embodiment, the two V H Bivalent binding agents, including single domain antibodies, have one or more or all of the following properties: high purity and stability, binding to human LAG-3, binding to T cells, and stimulation of T cells.
[0142] The bivalent binding agent is capable of binding strongly to the LAG-3-Fc protein, as shown in Example 8.
[0143] A bivalent binding agent may bind to LAG-3 protein or T cells with an EC50 value of up to 50 nM or less, e.g., about 10 nM, about 1 nM or about 0.1 nM or less, when LAG-3 binding is measured in an assay, e.g., as described in Example 8.
[0144] Bivalent binders can enhance T cell function. When human cells are stimulated with a superantigen (Staphylococcal enterotoxin B) and an anti-PD-1 antibody, the bivalent binders increase the secretion of inflammatory cytokines such as IL-2, indicating activation (Example 10a). Reporter cells measuring T cell signaling through the NFAT signaling pathway are stimulated when LAG-3 is blocked with bivalent molecules, generating IC50 values of at least 3 nM (Example 9b).
[0145] For example, the bivalent binding agent retains greater than 95% purity after heating at 40° C. as measured by size exclusion chromatography.
[0146] Multispecific Binding Agents In certain embodiments, the antibodies bind to LAG-3, block the functional interaction of LAG-3 with one or more of its ligands, and bind to one or more of the V ligands described herein. H Multispecific binding agents are provided which comprise an sdAb and also bind to additional targets. Multispecific binding agents bind to at least two different targets, i.e. are at least bispecific.
[0147] Bispecific antibody formats are generally known in the art. Typically, bispecific antibodies are divided into two categories: immunoglobulin G (IgG)-like molecules and non-IgG-like molecules, as described in Fan et al. (Journal of Hematology & Oncology (2015) 8:130). IgG-like bsAbs retain Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). As described below, in a preferred embodiment, the bispecific molecules of the present invention do not have an Fc domain.
[0148] The multispecific binding agents provided herein have binding specificity for LAG-3 as described herein and include at least one V H The antibody comprises a single domain antibody and at least one second binding molecule having a second binding specificity with a second antigen that is not LAG-3. The binding entities are linked by a linker, such as a peptide linker. The second binding molecule may be selected from an antibody, an antibody fragment or an antibody mimetic. In one embodiment, the antibody fragment is selected from a F(ab')2, Fab, Fv, sFv or a domain antibody. In one preferred embodiment, the antibody fragment is a V H A preferred embodiment is a single domain antibody. Thus, a preferred embodiment is a single V domain antibody with binding specificity for LAG-3. H Single domain antibodies are the second V H Concerning binding molecules linked to single domain antibodies.
[0149] Thus, in one embodiment, we provide a binding molecule having the formula: H (A)-LV H (B), where V H (A) V binds to LAG-3. H Single domain antibody, V H (B) V binds to a second target H A single domain antibody, wherein L is a linker, such as a peptide linker.
[0150] In one embodiment, the binding agent is bispecific, having binding specificity for LAG-3 as described herein and a V H The antibody comprises a single domain antibody selected from single domain antibodies, and a second binding molecule having a second binding specificity.
[0151] In another embodiment, the inventors provide two or more Vs that bind to LAG-3 as described herein, linked to a further moiety that binds to a second target, in particular as described in the bivalent molecule section above. H The bispecific binding agent as described above comprises a single domain antibody. H A single domain antibody may be selected, which has the formula: H (A')-L1-V H (A')-L2-V H (B), where L1 and L2 are linkers, e.g., peptide linkers. L1 and L2 can be the same linker or different linkers.
[0152] In one embodiment, the second binding molecule binds to an immunomodulatory agent, a checkpoint modulator, an agent involved in T cell activation, a tumor microenvironment modifier (TME), or a tumor-specific target.
[0153] For example, the immunomodulatory agent can be an inhibitor of an immune checkpoint molecule selected from one or more inhibitors of PD-L1, PD-L2, CTLA-4, TIM-3, PD-1, CEACAM, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFRβ. In another embodiment, an immunomodulatory agent can be an activator of costimulatory molecules selected from one or more agonists of IL-2, IL-12, OX40, OX40L, CD2, CD3, CD27, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, B7-H4 or CD83 ligand, CD3, CD8, CD28, CD4 or ICAM-1.
[0154] For example, the inventors have developed a V H Two Vs that bind to LAG-3 linked to single domain antibodies H Multispecific binding agents, including single domain antibodies, are provided, such that such formats have enhanced potency compared to monovalent entities.
[0155] Blockade of both PD-1 and LAG-3 is a promising combination strategy for cancer treatment, especially given that both PD-1 and LAG-3 regulate T cell activation. Thus, in one embodiment, the inventors provide a binding molecule having the following formula: H (A)-LV H (B) or preferably V H (A)-LV H (A)-LV H (B), where V H (A) V binds to LAG-3. H Single domain antibody, V H (B) V binds to PD-1. H A single domain antibody, wherein L is a linker, such as a peptide linker.
[0156] By simultaneously targeting the immune checkpoints PD-1 and LAG-3, the binding agents of the disclosure generate potent anti-tumor and / or anti-infection responses, increase anti-tumor lymphocyte cell activity, and enhance anti-tumor immunity, thereby resulting in at least additive or synergistic anti-tumor outcomes.
[0157] Indeed, the present inventors have demonstrated that V H Single domain antibodies and V that bind to PD-1 H We have shown that combining LAG-3 with single domain antibodies in bi- or multispecific fusion proteins results in enhanced function compared to monovalent entities. Furthermore, as described elsewhere, the bispecific molecules of the invention bind to cells expressing both LAG-3 and PD-1, in contrast to the universal blockade resulting from combination therapy. The bispecific molecules of the invention selectively bind to and activate such double positive cells, and reduce the blockade of PD-1 positive cells, i.e., cells that only display PD-1 on their surface. Thus, we have demonstrated that V that binds LAG-3 H Single domain antibodies and V that bind to PD-1 H Thus, in a preferred embodiment, the present invention provides a bi- or multispecific molecule comprising a single domain antibody. H A single domain antibody, and at least one V that binds to PD-1. H The present invention provides a binding agent that comprises a single domain antibody and binds to LAG-3 and PD-1 on the same cell, and does not contain other antibody fragments such as an Fc region.
[0158] These molecules specifically bind to wild-type human PD-1 (UniProt Accession No. Q15116, GenBank Accession No. U64863), the amino acid sequence of wild-type human PD-1 being shown below (SEQ ID NO: 12).
[0159] MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRV TERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSPARRGSADGPRSAQPLRPEDGHCSWPL
[0160] Unless otherwise specified, the term PD-1 as used herein refers to human PD-1. The terms "Programmed Death 1", "Programmed Cell Death 1", "protein PD-1", "PD-1", "PD-1", "PDCD1", "hPD-1" and "hPD-1" are used interchangeably and include variants, isoforms, and species homologs of human PD-1.
[0161] The terms "PD-1 binding molecule / protein / polypeptide / agent", "PD-1 antigen binding molecule protein / polypeptide / agent", "anti-PD-1 single domain antibody", "anti-PD-1 single immunoglobulin variable domain", "anti-PD-1 heavy chain only antibody" or "anti-PD-1 antibody" all refer to a molecule capable of specifically binding to the human PD-1 antigen. A binding reaction can be demonstrated by standard methods, for example with reference to a negative control test using an antibody of irrelevant specificity. The term "PD-1 binding molecule / agent" includes PD-1 binding proteins.
[0162] PD-1-binding V for use in bi- or multispecific fusion proteins HSingle domain antibodies have one or more of the following properties: bind to human PD-1 with high affinity, modulate the interaction of PD-1 with PD-L1 and / or PD-L2, block the functional interaction of PD-1 with PD-L1 and / or PD-L2, and / or stimulate or enhance T cell activation.
[0163] Accordingly, in another aspect, the invention provides binding molecules which include single domain antibodies which bind to human LAG-3 as described herein, which include single domain antibodies which bind to human PD-1, which block the interaction of PD-1 with PD-L1 and / or the interaction of PD-1 with PD-L2, and / or which stimulate or enhance T cell activation as described herein.
[0164] PD-1-binding V for use in bi- or multispecific fusion proteins H Single domain antibodies have one or more or all of the following properties: (a) binds to human PD-1; (b) increase IL-2 secretion in the MLR assay; (c) binds to human PD-1 and cynomolgus monkey PD-1; (d) does not bind to mouse PD-1; (e) inhibiting the binding of PD-L1 and / or PD-L2 to PD-1; and / or (f) inhibiting tumor cell proliferation in vivo;
[0165] PD-1 binding V H The single domain antibody can specifically bind human PD-1 with high affinity, with a KD of 10 or less as measured by surface plasmon resonance (Biomolecular Interaction Analysis, BIAcore® analysis). -8 M, 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 At least about 10 of M -8 M~10 -12 M. PD-1 binding V H Single domain antibodies have been shown to be highly effective in detecting 10-8 M~10 -9 The bispecific constructs may have IC50 values for PD-1 inhibition in the range of M. As shown in the Examples, the potency of the bispecific constructs against PD-1 positive cells is more than 30-fold lower than monoclonal antibodies.
[0166] In some embodiments, V H The single domain antibodies block the binding of PD-1 to PD-L1, PD-L2, and / or stimulate or enhance T cell activation and are selected from Table 5. H has been shown to have one or more or all of the above properties a) through f).
[0167] V binds to PD-1 H Single domain antibodies may be selected from those disclosed in WO2018127710, which is incorporated herein by reference.
[0168] [Table 5] JPEG2024156719000006.jpg225167 JPEG2024156719000007.jpg222167 JPEG2024156719000008.jpg228163 JPEG2024156719000009.jpg227165 JPEG2024156719000010.jpg227162 JPEG2024156719000011.jpg168168
[0169] These are encoded by the nucleic acids having SEQ ID NOs: 128-242.
[0170] In one embodiment, the V that binds to PD-1 H is the V shown above H2.63, 2.77 or 2.92 (SEQ ID NO: 104), or a sequence having at least 75%, such as 80%, 85%, 90% or 95% homology or identity thereto. H is V H 2.63. In one embodiment, V H is V H 2.77. In one embodiment, V H is V H The value is 2.92.
[0171] In one embodiment, the present inventors have identified a first V H Single domain antibody and second V that binds PD-1 H Bi- or multispecific molecules having single domain antibodies, i.e., a first single domain antibody of formula V having one or more of the following properties: H (A)-LV H (B) providing a molecule linked to the second single domain antibody: a) Binds to LAG-3 and PD-1 on the same cells; b) brings PD-1 and LAG-3 expressed on the same cells into physical proximity with greater potency than larger bispecific antibodies, as shown in Table 10; c) LAG-3 or PD-1V H binds to stimulated T cells with a median fluorescence intensity greater than that of either alone; d) stimulates IL-2 in superantigen-stimulated human PBMCs at levels higher than the combination of the individual units and higher than the combination of monoclonal antibodies against PD-1 and LAG-3; e) inhibits tumor growth in mouse models to a greater extent than clinical PD-1 monoclonal antibodies; f) PD-1V H induces greater proliferation of antigen-specific CD8+ T cells than either alone or LAG-3 blockade alone; g) induces proliferation of CD4 and CD8 T cells in patients to a greater extent than PD-1 monoclonal antibodies; h) significantly reduces inhibitory signaling in cells that do not respond to the combination; i) binds to LAG-3 with substantially higher affinity in the presence of PD-1; j) binds to PD-1 with substantially higher affinity in the presence of LAG-3: k) less potent PD-1 blockade in PD1+ single positive cells than PD-1 antibodies, but enhanced targeting of LAG-3+PD-1+ cells; and / or l) T cells can be recovered in an ex vivo system (see Example 8).
[0172] In another embodiment, the present inventors have identified one or more V H A single domain antibody, H A single domain antibody that binds to PD-1 as described herein. H Bi- or multispecific binding agents linked to single domain antibodies are provided. In one embodiment, a V that binds to PD-1 is provided. H The single domain antibodies may be any of the V domain antibodies listed in Table 5. H and single domain antibodies. In one embodiment, the bi- or multispecific binding agent has one or more of the properties a) to f) listed above.
[0173] In some embodiments, the PD-1 binding V H Single domain antibodies are the above single domain antibodies that bind to human PD-1. H A variant of any of the domain antibodies. The term variant is defined elsewhere herein. For example, a variant may be a V H 2.1, having 1 to 20, such as 1 to 10 or 1 to 5 amino acid substitutions. H and having at least 75%, for example 80%, 85%, 90% or 95% sequence homology or identity thereto.
[0174] In one embodiment, the bispecific molecule comprises one single domain antibody that binds to LAG-3 as described herein, hi another embodiment, the bispecific molecule comprises two single domain antibodies that bind to LAG-3 as described herein.
[0175] In another aspect, the inventors also provide a bispecific binding agent that binds PD-1 and LAG-3, comprising two single domain antibodies that bind LAG-3 and one single domain antibody that binds PD-1. In one embodiment, the two single domain antibodies that bind LAG-3 are as described above. In one embodiment, the single domain antibody that binds PD-1 is as described above. The inventors have surprisingly demonstrated that such a binding agent comprising two single domain antibodies that bind LAG-3 has enhanced potency compared to a binding agent comprising one single domain antibody that binds LAG-3. This can be seen in FIG. 3c, which shows enhanced stimulation of IL-2 release. Having two single domain antibodies that bind LAG-3 linked to a single domain antibody that binds PD-1 in a bi- or multispecific molecule provides at least an additive effect compared to a binding agent with one single domain antibody that binds LAG-3. Thus, in one embodiment, the molecule has the formula: V H (A)-L1-V H (A)-L2-V H (B), optionally including additional C-terminal portions and / or sequences. Thus, there are two single domain antibodies of the same sequence that bind to LAG-3 and one single domain antibody that binds to PD-1. Exemplary molecules are as follows: H 1.1-LV H 1.1-LV H 2.63;V H 1.1-LV H 1.1-LV H 2.63;V H 2.77-LV H 1.1-LV H 1.1; and V H 1.2-LV H 1.2-LVH 2.92. In one embodiment, the molecule is V H 1.2-LV H 1.2-LV H 2.92. L is a linker as further defined herein.
[0176] In one embodiment, the molecule is H 1.1-6GS-V H 1.1-6GS-V H 2.63;V H 1.1-6GS-V H 1.1-9GS-V H 2.63;V H 2.77-9GS-V H 1.1-6GS-V H 1.1; and V H 1.2-6GS-V H 1.2-6GS-V H 2.92. In one embodiment, the molecule is selected from V H 1.2-6GS-V H 1.2-6GS-V H 2.92 (sequence number 259).
[0177] In another embodiment, the bispecific binding agent, i.e., fusion protein, that simultaneously binds LAG-3 and PD-1 as described above, comprises an additional binding molecule. Thus, the binding agent may be trispecific or tetraspecific. Additional specificities are also envisioned. Any combination of the above molecules can be made into a multispecific binding agent, e.g., a trispecific binding agent comprising a single domain antibody that binds to LAG-3 and a second and third binding specificity. For example, as described in detail below, the third binding specificity can be for human serum albumin (HSA). Thus, the binding agent can comprise the following components: one or two Vs that bind to LAG-3, as described herein and selected, e.g., from Table 1. H Single domain antibody, V that binds to PD-1 H Single domain antibodies and V that bind to HSA HSingle domain antibodies. The entities are linked via a linker as described herein. The order of the entities can be arbitrary, for example, V that binds to PD-1. H Single domain antibodies can be located at the C-terminus or N-terminus.
[0178] Thus, in another aspect we provide a multispecific binding agent as described above which comprises a further moiety which binds to a third target. H It may be a single domain antibody, for example having one of the following formulas: H (C)-L1-V H (A)-L2-V H (B), V H (A)-L1-V H (B)-L2-V H (C), V H (A')-L1-V H (A')-L2-V H (B)-L3-V H (C) or V H (C)-L1-V H (A')-L2-V H (A')-L3-V H (B). For example, V H (A) and V H (A') Both V bind to LAG-3. H Single domain antibody, V H (B) V binds to PD-1. H Single domain antibody, V H (C) V binds to HSA H It is a single domain antibody.
[0179] Although preferred embodiments relate to molecules comprising or consisting of single domain antibodies, i.e. molecules with no other antibody moieties, the invention also extends to molecules with two binding moieties that bind LAG-3 and one binding moiety that binds to another target, such as PD-1. Importantly, the inventors have shown that bispecific molecules that bind with high affinity to LAG-3 favour cells expressing both LAG-3 and PD-1, and have reduced binding to PD-1 single positive cells.
[0180] In yet another aspect, the inventors provide methods of simultaneously inhibiting immunity to PD-1 and LAG-3 by administering a binding agent described herein.
[0181] Conjugates with half-life-extending molecules or other moieties In one embodiment, the further moiety (e.g., a second or third, fourth, etc. moiety) may serve to extend the half-life of the binding molecule. The further moiety may comprise a protein, such as an antibody or portion thereof, that binds to serum albumin, such as human serum albumin (HSA) or mouse serum albumin (MSA). The further moiety may comprise a V that binds to serum albumin, such as human serum albumin (HSA) or mouse serum albumin (MSA). H It may include a domain.
[0182] The further moiety may comprise serum albumin, such as human serum albumin (HSA), or a variant thereof, such as HSA C34S. The half-life extending moiety may be attached to the C-terminus, N-terminus, or elsewhere within the binding molecule, such as a linked V H It may be located in a "chain" of a single domain antibody.
[0183] In one embodiment, the anti-LAG-3 single domain antibody or multivalent binding agent described herein is labeled with a detectable or functional label. The label can be any molecule that can generate or induce the generation of a signal, including, but not limited to, a fluorophore, a fluorescent substance, a radioactive label, an enzyme, a chemiluminescent substance, a nuclear magnetic resonance active label, or a photosensitizer. Thus, binding can be detected and / or measured by detecting fluorescence or luminescence, radioactivity, enzyme activity, or absorbance.
[0184] In yet another embodiment, the anti-LAG-3 single domain antibody or multivalent binding agent described herein is conjugated to at least one therapeutic moiety, such as a drug, enzyme or toxin, in one embodiment, the therapeutic moiety is a toxin, such as a cytotoxic radionuclide, a chemical toxin or a protein toxin.
[0185] In another embodiment, the anti-LAG-3 single domain antibodies or multivalent binding agents described herein are modified to increase their half-life, for example by chemical modification, in particular PEGylation, or by incorporation into liposomes, or by use of serum albumin protein.
[0186] The half-life is calculated based on the corresponding V H The half-life may be at least 1.5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times or more than 20 times longer than the half-life of a single domain antibody. For example, the increase in half-life may be greater than the half-life of a corresponding V H Compared to single domain antibodies it may be more than 1 hour, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours or even more than 24, 48 or 72 hours.
[0187] Linker In multivalent binding agents, the subunits can be linked via chemical or peptide linkers. The linkage can be covalent or non-covalent. A preferred covalent linkage is via a peptide bond. As described elsewhere, the multivalent binding agent is preferably in the form of a protein fusion. In some embodiments, the multivalent binding agents described herein, two or more binding molecules are connected by a linker, such as, for example, a polypeptide linker (L). Suitable linkers include, for example, linkers having GS residues, such as (Gly4Ser)n, where n=1-20, such as 1-12, such as 1-12, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12. In one embodiment, n=5, 6, 8 or 12.
[0188] Exemplary linkers are 2GS, 4GS, 6GS, 9GS, i.e., SEQ ID NOs: 243, 244, 245, 246, 247, 248, 249 or 250, respectively.
[0189] Other linkers will be known to those of skill in the art.
[0190] Exemplary Methods for Making Single Domain Antibodies The single domain antibodies described herein are obtained or can be obtained from transgenic rodents that express heavy chain-only antibodies upon stimulation with recombinant LAG-3 antigen as described in the Examples. The transgenic rodents, e.g. mice, preferably have a reduced capacity to express endogenous antibody genes. Thus, in one embodiment, the rodents have a reduced capacity to express endogenous light and / or heavy chain antibody genes. Thus, the rodents may contain modifications to block expression of endogenous kappa and lambda light chain and / or heavy chain antibody genes, such that no functional light and / or heavy chains are produced, e.g., as further described below. Exemplary methods for producing sdAbs of the invention are described below.
[0191] Methods for producing human heavy chain only antibodies capable of binding to human LAG-3 include: a) immunizing a transgenic rodent expressing a nucleic acid construct comprising an unrearranged human heavy chain V gene and incapable of producing a functional endogenous light or heavy chain with a LAG-3 antigen; b) Isolating human heavy chain-only antibodies Includes.
[0192] Further steps include, for example, isolating V from the mouse. H generating a library of sequences containing domain sequences and selecting V from the library; H By isolating a sequence containing the domain sequence, the V H This may include isolating the domain.
[0193] A single V capable of binding to human LAG-3 H The method for producing a domain antibody comprises: a) immunizing a transgenic rodent expressing a nucleic acid construct comprising an unrearranged human heavy chain V gene and incapable of producing a functional endogenous light or heavy chain with a LAG-3 antigen; b) V from said mouse H c) generating a library of sequences comprising domain sequences from said library; H Isolating a sequence containing a domain sequence Includes.
[0194] A further step is to identify a single V that binds to human LAG-3, for example by using a functional assay as shown in the Examples. H This may involve identifying domain antibodies or heavy chain only antibodies.
[0195] Methods for preparing or producing the polypeptides, nucleic acids, host cells, products and compositions described herein using an in vitro expression library may comprise the steps of: a) providing a set, collection or library of nucleic acid sequences encoding amino acid sequences; and b) screening said set, collection or library for amino acid sequences capable of binding / having affinity to LAG-3; and c) isolating amino acid sequences capable of binding to / having affinity for LAG-3.
[0196] In the above methods, the set, collection or library of amino acid sequences may be displayed on a phage, phagemid, ribosome or suitable microorganism (such as yeast) for ease of screening, etc. Suitable methods, techniques and host organisms for displaying and screening (sets, collections or libraries of) amino acid sequences will be apparent to those skilled in the art (see, for example, Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press; 1st edition (October 28, 1996) Brian K. Kay, Jill Winter, John McCafferty).
[0197] Libraries, such as phage libraries, are prepared by isolating cells or tissues that express antigen-specific heavy chain-only antibodies and generating V-proteins from mRNA derived from the isolated cells or tissues. H by cloning sequences encoding the domains and displaying the encoded proteins using a library. H The domains can be expressed in bacteria, yeast or other expression systems.
[0198] Another embodiment also comprises a human V H V that binds to LAG-3 containing the amino acid product of the germline sequence or an amino acid product derived therefrom H Isolated V H It relates to single domain antibodies or isolated heavy chain only antibodies, which may be fully human or may contain mouse sequences.
[0199] The term rodent relates to a mouse or a rat.
[0200] In one embodiment, the rodent is a mouse. The mouse may contain a non-functional endogenous λ light chain locus. Thus, the mouse does not produce a functional endogenous λ light chain. In one embodiment, the λ light chain locus is partially or completely deleted or rendered non-functional by insertion, inversion, recombination event, gene editing or gene silencing. For example, at least the constant region genes C1, C2 and C3 can be deleted or rendered non-functional by insertion or other modification as described above. In one embodiment, the locus is functionally silenced so that the mouse does not produce a functional λ light chain.
[0201] Furthermore, the mouse may comprise a non-functional endogenous κ light chain locus. Thus, the mouse does not produce a functional endogenous κ light chain. In one embodiment, the κ light chain locus is partially or completely deleted or rendered non-functional by insertion, inversion, recombination event, gene editing or gene silencing. In one embodiment, the locus is functionally silenced such that the mouse does not produce a functional κ light chain.
[0202] Mice with functionally silenced endogenous λ and κ L chain loci can be generated, for example, as disclosed in WO2003 / 000737, the entire contents of which are incorporated herein by reference.
[0203] Additionally, the mouse may comprise a non-functional endogenous heavy chain locus. Thus, the mouse does not produce a functional endogenous heavy chain. In one embodiment, the heavy chain locus is partially or completely deleted or rendered non-functional by insertion, inversion, recombination events, gene editing or gene silencing. In one embodiment, the locus is functionally silenced such that the mouse does not produce a functional heavy chain.
[0204] For example, as described in WO2004 / 076618 (hereby incorporated by reference in its entirety), all eight endogenous heavy chain constant region immunoglobulin genes (μ, δ, γ3, γ1, γ2a, γ2b, ε and α) are absent in the mouse, or are partially absent to the extent that they are non-functional, or genes δ, γ3, γ1, γ2a, γ2b and ε are absent and the adjacent genes μ and α are partially absent to the extent that they are non-functional, or genes μ, δ, γ3, γ1, γ2a, γ2b, ε and α are absent and α is partially absent to the extent that it is non-functional, or δ, γ3, γ1, γ2a, γ2b, ε and α are absent and μ is partially absent to the extent that it is non-functional. By partially deleted, it is meant that the endogenous locus gene sequence has been deleted or disrupted, e.g., by an insertion, to the extent that no functional endogenous gene product is encoded by the locus, i.e., no functional product is expressed from the locus. In another embodiment, the locus is functionally silenced.
[0205] In one embodiment, the mouse comprises a non-functional endogenous heavy chain locus, a non-functional endogenous λ light chain locus, and a non-functional endogenous κ light chain locus. Thus, the mouse does not produce functional endogenous light or heavy chains. Thus, the mouse is a triple knockout (TKO) mouse.
[0206] The transgenic mouse may contain a vector, such as a yeast artificial chromosome (YAC), for expressing a heterologous, preferably human, heavy chain locus. YAC is a vector that can be used for cloning very large DNA inserts in yeast. Not only does it contain all three cis-acting structural elements essential for working like a natural yeast chromosome (autonomously replicating sequence (ARS), centromere (CEN) and two telomeres (TEL)), but it also has the ability to accept large DNA inserts, allowing it to achieve the minimum size (150 kb) required for chromosome-like stability and fidelity of transmission in yeast cells. The construction and use of YACs are well known in the art (e.g., Bruschi, CV and Gjuracic, K. Yeast Artificial Chromosomes, Encyclopedia of Life Sciences, 2002 Macmillan Publishers Ltd, Nature Publishing Group).
[0207] For example, YAC is H 1 domain, mouse enhancer and regulatory regions, combined with a mouse immunoglobulin constant region gene lacking the mouse V H It can contain multiple V, D and J genes. H , D and J genes are V in humans H , D and J loci, which are unrearranged genes that are completely human.
[0208] Another method known in the art is H Deletion or inactivation of endogenous mouse or rat immunoglobulin genes, as well as human V1 domains, mouse enhancers and regulatory regions, in combination with mouse immunoglobulin constant region genes lacking H It can be used to introduce D and J genes.
[0209] Transgenic mice can be produced according to standard techniques, as shown in the examples. The two most well-characterized routes for producing transgenic mice are pronuclear microinjection of genetic material into oocytes immediately after fertilization, or the introduction of stably transfected embryonic stem cells into morula or blastocyst stage embryos. Regardless of how genetic material is introduced, the treated embryos are transferred into pseudopregnant female recipients, pregnancy is continued, and transgenic candidate offspring are born.
[0210] The main difference between these widespread methods is that ES clones can be extensively screened before being used to generate transgenic animals. In contrast, pronuclear microinjection relies on the genetic material being integrated into the host genome after introduction, and generally speaking, successful incorporation of the transgene cannot be confirmed until offspring are born.
[0211] There are many methods known in the art to aid and determine whether transgene integration is successful. Transgenic animals can be generated by multiple means, including random integration of constructs into the genome, site-specific integration, or homologous recombination. There are a variety of tools and techniques that can be used to both facilitate and select for transgene integration and subsequent modification, including the use of drug resistance markers (positive selection), recombinases, recombination-mediated cassette exchange, negative selection techniques, and nucleases to improve the efficiency of recombination. Most of these methods are commonly used in the modification of ES cells. However, some of these techniques may be useful to enhance genetic recombination mediated via pronuclear injection.
[0212] Further improvements can more efficiently generate transgenic lines in the desired background. As described above, in a preferred embodiment, endogenous mouse immunoglobulin expression is silenced to allow the introduced transgene to be used solely for the expression of a heavy chain-only repertoire that can be exploited for drug discovery. A genetically engineered mouse, for example a TKO mouse in which all endogenous immunoglobulin loci (mouse heavy chain, mouse kappa chain and mouse lambda chain) are silenced, can be used as described above. The introduction of the introduced transgene into this TKO background can be achieved by traditional breeding methods or by incorporating an IVF step to efficiently scale the process. However, it is also possible to include the TKO background during the genetic engineering procedure. For example, in the case of microinjection, oocytes are derived from a TKO donor. Similarly, ES cells from TKO embryos can be derived for use in genetic transfer.
[0213] A triple knockout mouse in which transgenes have been introduced to express immunoglobulin loci is referred to herein as TKO / Tg. In one embodiment, the mouse is as described in WO2016 / 062990, which is incorporated herein in its entirety.
[0214] Exemplary Pharmaceutical Compositions In another aspect, there is provided a pharmaceutical composition comprising a binding molecule of the invention, e.g., a binding molecule as described herein, including a single domain antibody that binds to LAG-3, including a single domain antibody that binds to LAG-3, as disclosed herein, or a bispecific molecule as described herein that binds to both LAG-3 and PD-1, and optionally a pharma- ceutically acceptable carrier. The single domain antibody, binding molecule or pharmaceutical composition described herein may be administered by any convenient route, including, but not limited to, oral, topical, parenteral, sublingual, rectal, intravaginal, intraocular, intranasal, intrapulmonary, intradermal, intravitreal, intratumoral, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topically, particularly to the ear, nose, eye or skin, or by inhalation. In another embodiment, the delivery is of a nucleic acid encoding a drug, e.g., a nucleic acid encoding a molecule of the invention.
[0215] Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical, or subcutaneous administration. Preferably, the compositions are administered parenterally.
[0216] The pharma- ceutically acceptable carrier or vehicle may be particulate, so that the composition is, for example, in tablet or powder form. The term "carrier" refers to a diluent, adjuvant, or excipient with which the drug antibody conjugate of the present invention is administered. Such pharmaceutical carriers may be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. The carrier may be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. Additionally, auxiliary, stabilizing, thickening, lubricating, and coloring agents may be used. In one embodiment, the single domain antibody or composition of the present invention and the pharma- ceutically acceptable carrier are sterile when administered to an animal. When the drug antibody conjugate of the present invention is administered intravenously, water is a preferred carrier. Saline and aqueous dextrose and glycerol solutions may also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, etc. The compositions of the present invention, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0217] The pharmaceutical composition may be in the form of a liquid, such as a solution, syrup, liquid, emulsion or suspension, which may be useful for oral administration or for delivery by injection, infusion (e.g., intravenous infusion) or subcutaneously.
[0218] When intended for oral administration, the compositions may be in solid or liquid form, with semi-solid, semi-liquid, suspension and gel forms being included in the forms considered herein as either solid or liquid.
[0219] As a solid composition for oral administration, the composition can be formulated into powder, granules, compressed tablets, pills, capsules, chewing gum, wafers, etc. Such solid compositions typically contain one or more inert diluents. In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose, or dextrin; disintegrants such as alginic acid, sodium alginate, corn starch, etc.; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; flavors such as peppermint, methyl salicylate, or orange flavor; and colorants. When the composition is in the form of a capsule (e.g., gelatin capsule), in addition to the above types of materials, liquid carriers such as polyethylene glycol, cyclodextrin, or fatty oils can be included.
[0220] When intended for oral administration, the composition may contain one or more sweeteners, preservatives, dyes / colorants and flavor enhancers. A composition for administration by injection may also contain one or more surfactants, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers and isotonic agents.
[0221] The compositions may be in the form of one or more dosage units.
[0222] In certain embodiments, it may be desirable to administer the composition locally to the area in need of treatment or by intravenous injection or infusion.
[0223] The amount of the single domain antibody or binding molecule described herein that is effective / active in treating a particular disease or condition will depend on the nature of the disease or condition and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can be optionally used to help identify optimal dosage ranges. The exact dose to be used in the composition will also depend on the route of administration and the severity of the disease, and should be determined according to the judgment of the practitioner according to each patient's circumstances. Factors such as age, body weight, sex, diet, time of administration, excretion rate, condition of the host, drug combination, reaction sensitivity and severity of the disease will be taken into account.
[0224] Typically, the amount will be at least about 0.01% of a single domain antibody of the invention by weight of the composition. If oral administration is intended, this amount may vary from about 0.1% to about 80% by weight of the composition. A preferred oral composition may contain from about 4% to about 50% of an sdAb of the invention by weight of the composition.
[0225] The compositions may be prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the single domain antibody of the invention.
[0226] For administration by injection, the composition may typically contain about 0.1 mg / kg to about 250 mg / kg of the animal's body weight, preferably about 0.1 mg / kg to about 20 mg / kg of the animal's body weight, more preferably about 1 mg / kg to about 10 mg / kg of the animal's body weight. In one embodiment, the composition is administered at a dose of about 1 to 30 mg / kg, e.g., about 5 to 25 mg / kg, about 10 to 20 mg / kg, about 1 to 5 mg / kg, or about 3 mg / kg. The dosing schedule may vary, for example, from once a week to once every 2, 3, or 4 weeks.
[0227] In another aspect, the present inventors provide an isolated anti-LAG-3V antibody as described herein. HCAR constructs are provided that comprise the single domain antibodies or multispecific binding agents described herein, particularly the binding agents described herein that have single domain antibodies against both PD-1 and LAG-3.
[0228] CARs are synthetic receptors that typically consist of a targeting / binding moiety associated with one or more signaling domains in a single fusion molecule. The binding moiety of a CAR typically consists of the antigen-binding domain of a single-chain antibody (scFv), which contains the variable fragments of the light and heavy chains of a monoclonal antibody joined by a flexible linker. The scFv retains the same specificity and similar affinity as the full antibody from which it is derived and can bind to a specific target of interest. When the CAR construct is expressed on the surface of a T cell and binds to its target protein, it triggers T cell activation. T cell activation is a powerful weapon, and therefore nonspecific activation of T cells is a major safety concern. Although scFvs are typically used as targeting agents, they have several properties that may adversely affect the therapeutic efficacy of CAR-T. scFvs are characterized by low expression and stability, and a tendency to unfolding and aggregation. As a result, they often make CAR expression difficult to achieve or are nonspecific for T cell targeting and nonspecific for initiating signaling. CAR-Ts bearing scFvs can also form clusters on the membrane by cross-linking the heavy and light chains of different CAR-Ts, which leads to unwanted constitutive signaling.
[0229] Furthermore, the scFvs used in CAR-Ts are also usually derived from mouse mAbs and therefore pose potential immunogenicity issues as anti-scFv responses could potentially initiate T cell responses by cross-linking as well as clear CAR-Ts from circulation.
[0230] Without intending to be bound by theory, these problems tend to be exacerbated when using scFvs to design CAR-Ts with bispecific, bivalent or biparatopic antigen-binding moieties. Thus, in one embodiment, the present invention relates to an isolated CAR having an antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the antigen-binding domain is an isolated anti-LAG-3V antibody as described herein. H The present invention also relates to an isolated nucleic acid encoding a CAR according to the present invention. The present invention also relates to a vector comprising a nucleic acid of the present invention. In another aspect, the present invention also relates to a host cell comprising a nucleic acid or vector of the present invention. The present invention also relates to an isolated cell or cell population comprising one or more CARs of the present invention. Such cells are genetically modified to express a CAR of the present invention. In one embodiment, the cell is a T cell (CAR-T). The present invention further relates to a method of treating cancer comprising administering a T cell or pharmaceutical composition of the present invention.
[0231] Exemplary Therapeutic Applications The present invention also relates to therapeutic uses of the LAG-3 binding molecules of the invention. In one embodiment, we provide a method for treating a LAG-3 mediated disease in a mammal, e.g., a human patient, comprising administering to the mammal in need thereof an effective amount of a binding molecule of the invention, e.g., a binding molecule comprising at least one single domain antibody that binds to LAG-3 as described herein.
[0232] As used herein, "treat," "treating," or "treatment" refers to inhibiting or alleviating a disease. For example, treatment can include postponing the onset of symptoms associated with the disease and / or reducing the severity of such symptoms that occur or are expected to occur with the disease. The term includes amelioration of existing symptoms, prevention of additional symptoms, and amelioration or prevention of the underlying causes of such symptoms. Thus, these terms indicate that a beneficial result has been achieved in at least a portion of the mammal, e.g., human patient, being treated. Many medical treatments are effective in some, but not all, patients receiving the treatment.
[0233] The term "subject" or "patient" refers to an animal that is the object of treatment, observation or experiment. By way of example only, a subject includes a mammal, including, but not limited to, a human or a non-human primate, a non-human mammal such as, but not limited to, a mouse, a cow, a horse, a dog, a sheep, or a cat.
[0234] As used herein, the term "effective amount" means an amount of an anti-LAG-3 antibody that, when administered alone or in combination with additional therapeutic agents to a cell, tissue or subject, is effective to achieve the desired therapeutic or prophylactic effect under the circumstances in which it is administered.
[0235] The present invention also relates to a single domain antibody, binding molecule or pharmaceutical composition as described herein for use in the treatment or prevention of disease.
[0236] In another aspect, the invention relates to the use of a single domain antibody, binding molecule or pharmaceutical composition as described herein in the treatment or prevention of disease.
[0237] In another aspect, the disclosure relates to the use of a single domain antibody or binding molecule as described herein in the manufacture of a medicament for the treatment or prevention of a disease listed herein.
[0238] The disease may be selected from cancer, immune diseases, neurological diseases, inflammatory diseases, allergies, transplant rejection, viral infections, immunodeficiencies and other immune system related diseases.
[0239] In one embodiment, the disease is cancer.Cancer can be selected from solid tumors or non-solid tumors.For example, cancer can be selected from osteosarcoma, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, breast cancer, brain cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, kidney cancer, soft tissue sarcoma, urethral cancer, bladder cancer, renal cancer, lung cancer, non-small cell lung cancer, thymoma, prostate cancer, mesothelioma, adrenocortical carcinoma, lymphoma such as Hodgkin's disease and non-Hodgkin's disease, gastric cancer, ALL, CLL, AML, urothelial cancer, leukemia such as leukemia and multiple myeloma.
[0240] In one embodiment, the tumor is a solid tumor. Examples of solid tumors that can be treated accordingly include breast cancer, lung cancer, colon cancer, pancreatic cancer, glioma and lymphoma. Some examples of such tumors include epidermoid tumors, squamous cell tumors such as head and neck tumors, colon tumors, prostate tumors, breast tumors, lung tumors including small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors and liver tumors. Other examples include Kaposi's sarcoma, CNS, neoplasms, neuroblastoma, capillary hemangioblastoma, meningioma and brain metastases, melanoma, gastrointestinal and renal cancer and sarcoma, rhabdomyosarcoma, glioblastoma, preferably glioblastoma multiforme, and leiomyosarcoma. Examples of angiogenic skin cancers that the antagonists of the present invention are effective against include squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be treated by suppressing the proliferation of malignant keratinocytes, such as human malignant keratinocytes.
[0241] In one embodiment, the tumor is a non-solid tumor. Examples of non-solid tumors include leukemia, multiple myeloma, and lymphoma.
[0242] In one embodiment, the cancer is locally advanced unresectable, metastatic or recurrent cancer.
[0243] Cancers include those whose growth can be inhibited using the antibody of the present invention, and include cancers that typically respond to immunotherapy.Non-limiting examples of cancers that are preferred for treatment include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory prostate cancer), breast cancer, colon cancer, and lung cancer (e.g., non-small cell lung cancer).
[0244] In one embodiment, the cancer progresses after another treatment, such as chemotherapy. In one embodiment, the patient is a cancer patient treated with anti-PD-1 or anti-PD-L1 therapy. In one embodiment, the patient is selected from PD1 refractory patients.
[0245] The expected improved targeting to double-positive cells may mean improved safety.
[0246] Immunologic disorders include graft-versus-host disease, arthritis, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune disorders of the adrenal glands, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune urethritis and orchitis, autoimmune thrombocytopenia, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, lupinus syndrome, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barré, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, juvenile In some embodiments, the disease may be selected from: chronic arthritis, lichen planus, lupus multiple sclerosis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, neuromyelitis optica (NMO), type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, rheumatic polymyositis, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary hepatitis, psoriasis, psoriatic arthritis, Raynaud's syndrome, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-person syndrome, systemic lupus erythematosus, lupus erythematosus, Takayasu's arteritis, temporal arteritis / giant cell arteritis, transverse myelitis, ulcerative colitis, uveitis, vasculitis such as dermatitis herpetiformis vasculitis, vitiligo and Wegener's granulomatosis.
[0247] We have demonstrated that sdAbs that bind to LAG-3 can block the interaction of LAG-3 with α-synuclein. Alpha-synuclein (also α-synuclein) is a presynaptic neuronal protein that is genetically and neuropathologically linked to Parkinson's disease. Although α-synuclein may contribute to the pathogenesis of PD in several ways, it is generally believed that its abnormal soluble oligomeric structures, called prefibrils, are toxic species that mediate the disruption of cellular homeostasis and neuronal death through their effects on various intracellular targets, including synaptic function. Targeting the toxic functions conferred by this protein when dysregulated may provide new therapeutic strategies not only in PD but also in other neurodegenerative conditions called synucleinopathies (Stefanis, Cold Spring Harb Perspect Med. 2012 Feb; 2(2)).
[0248] Thus, in one embodiment of the above aspect, the disease is a neurological disease, such as a synucleinopathy. The neurological disease may be selected from Alzheimer's disease, epilepsy, Parkinson's disease, dementia, multiple sclerosis, peripheral neuropathy or post-herpetic neuralgia.
[0249] In one embodiment, the disease is selected from an infectious disease such as HIV, HCV or a parasitic infection.
[0250] The single domain antibody, binding molecule or pharmaceutical composition described herein can be administered as a single active ingredient or in combination with one or more other therapeutic agents.Therapeutic agents are compounds or molecules that are useful for treating disease.Examples of therapeutic agents include antibodies, antibody fragments, drugs, toxins, nucleases, hormones, immunomodulators, proapoptotic agents, antiangiogenic agents, boron compounds, photoactive agents or dyes, and radioisotopes.
[0251] In one embodiment, the single domain antibodies, binding molecules or pharmaceutical compositions described herein are used in combination with existing treatments or therapeutic agents, such as anti-cancer treatments. Thus, in another aspect, the present invention also relates to combination therapies comprising the administration of the single domain antibodies or pharmaceutical compositions of the present invention and anti-cancer therapies, including therapeutic or radiation therapy, including gene therapy, viral therapy, RNA therapy, bone marrow transplantation, nanotherapy, targeted anti-cancer therapy or oncolytic drugs. Examples of other therapeutic agents include other checkpoint inhibitors, anti-tumor drugs, immunogenic drugs, attenuated cancer cells, tumor antigens, tumor-derived antigens or antigen-presenting cells such as dendritic cells stimulated with nucleic acids, immune stimulatory cytokines (e.g., IL-2, IFNa2, GM-CSF), targeted small molecules and biomolecules (such as agents that bind to tumor-specific antigens including components of signal transduction pathways, e.g., modulators of tyrosine kinases and inhibitors of receptor tyrosine kinases, and EGFR antagonists), anti-inflammatory agents, cytotoxic agents, radiotoxic agents, or immunosuppressants, and cells transfected with genes encoding immune stimulatory cytokines (e.g., GM-CSF), chemotherapy. In one embodiment, single domain antibodies are used in combination with surgery.
[0252] In one embodiment, the single domain antibody, binding agent or pharmaceutical composition described herein is administered in combination with an immunomodulatory agent, a checkpoint modifier, an agent involved in T cell activation, a tumor microenvironment modifier (TME) or a tumor-specific target. For example, the immunomodulatory agent can be an inhibitor of an immune checkpoint molecule selected from one or more inhibitors of PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, CEACAM, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFRβ. In another embodiment, the immunomodulatory agent can be an activator of costimulatory molecules selected from one or more agonists of OX40, OX40L, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand, CD3, CD8, CD28, CD4 or ICAM-1.
[0253] In certain embodiments of the present invention, the composition is administered simultaneously with chemotherapy or radiation therapy.In another particular embodiment, chemotherapy or radiation therapy is administered before or after the administration of the composition of the present invention, preferably at least 1 hour, 5 hours, 12 hours, 1 day, 1 week, 1 month, more preferably before or after the administration of the composition of the present invention, several months (for example, up to 3 months).
[0254] In some embodiments, the single domain antibodies or binding agents described herein may be administered with two or more therapeutic agents. In some embodiments, the binding agents of the invention may be administered with two or more therapeutic agents.
[0255] The single domain antibodies, pharmaceutical compositions or binding molecules described herein may be administered at the same time or at different times, e.g., simultaneously, separately or sequentially, as other therapeutic or therapeutic compounds or treatments.
[0256] In yet another aspect, we provide a method of modulating an immune response in a subject comprising administering to the subject a single domain antibody, pharmaceutical composition or binding molecule as described herein to modulate the immune response in said subject. In one embodiment, the single domain antibody, pharmaceutical composition or binding molecule as described herein enhances, stimulates or increases the immune response in the subject.
[0257] In a further aspect, we provide a method of inhibiting the proliferation of tumour cells in a subject comprising administering to the subject a therapeutically effective amount of a single domain antibody, pharmaceutical composition or binding molecule as described herein.
[0258] In a further aspect, we provide a method for selectively targeting cells presenting PD-1 and LAG-3 on their surface, for example by providing a binding agent of the invention, e.g. by administering such a binding agent to a patient. In a further aspect, we provide a method for dual blockade of PD-1 and LAG-3 on their surface, for example by providing a binding agent of the invention, e.g. by administering such a binding agent to a patient. In one embodiment, the method is an in vitro or ex vivo method.
[0259] In another aspect, the present invention relates to an immunoconjugate comprising a single domain antibody, pharmaceutical composition or binding molecule as described herein conjugated to at least one therapeutic and / or diagnostic agent.
[0260] The inventors have also confirmed that the E3 ubiquitin ligases Cbl-b and / or c-Cbl can be used as predictive biomarkers for treatment with bispecific anti-LAG+anti-PD1 binding molecules. Prognostic biomarkers provide information about the overall cancer outcome of a patient, regardless of the treatment, whereas predictive biomarkers provide information about the efficacy of a therapeutic intervention. Thus, the present invention also relates to the use of Cbl-b and / or c-Cbl as predictive biomarkers in cancer treatment with bispecific anti-LAG+anti-PD1 binding molecules. The present invention also relates to the use of Cbl-b and / or c-Cbl as predictive biomarkers in cancer treatment with bispecific anti-LAG+anti-PD1 binding molecules, e.g., as described herein. H 1.2-LV H 1.2-LV H A method for identifying subjects who will respond to the treatment using bispecific anti-LAG+anti-PD1 binding molecules such as 2.92 by measuring the protein or RNA expression of Cbl-b and / or c-Cbl in subjects or samples from subjects treated with the bispecific treatment. Suppression or reduction in the expression of Cbl-b and / or c-Cbl indicates that the subject will respond to the treatment. This is supported by the data in Example 9 showing the association of these markers with cell proliferation.
[0261] We also provide a method for providing a prediction of the outcome of a treatment for a subject having cancer or for selecting a treatment for a subject suffering from cancer, the method comprising: a) a biological sample from a subject and, for example, a V H 1.2-LV H 1.2-LV H 2. Contacting with a bispecific anti-LAG+anti-PD1 binding molecule such as 92; b) measuring the protein or RNA expression of Cbl-b and / or c-Cbl in the sample; c) determining a risk score for the subject based on the protein or RNA expression level of Cbl-b and / or c-Cbl in the sample; and d) providing a prognosis of response to treatment with the bispecific binding molecule based on the subject's risk score. Includes.
[0262] In one aspect, we provide a method of treating a subject with cancer, comprising predicting a level of response to treatment in a subject with cancer, the method comprising: a) a biological sample from a subject and, for example, a V H 1.2-LV H 1.2-LV H 2. Contacting with a bispecific anti-LAG+anti-PD1 binding molecule such as 92; b) measuring the protein or RNA expression of Cbl-b and / or c-Cbl in the sample; c) determining a risk score for the subject based on the protein or RNA expression levels of Cbl-b and / or c-Cbl in the sample; d) comparing the risk score to a threshold to predict whether the subject is likely to respond to treatment with the bispecific binding molecule; e) choosing a treatment; and f) Providing medical treatment Includes.
[0263] In one embodiment, the treatment is with a bispecific molecule described herein.
[0264] In one embodiment, the sample is incubated with the bispecific binding agent. In one embodiment, the sample is a blood sample. In one embodiment, T cells are isolated from the blood sample and incubated with the agent. Expression of Cbl-b and / or c-Cbl can be measured using standard methods, for example, using agents that bind to proteins or RNAs containing primers. Kits for use in the above methods are also provided, which contain reagents that bind to Cbl-b and / or c-Cbl and can be used to measure protein or nucleic acid expression.
[0265] Kits and Diagnostic Tests In another aspect, the present invention provides a kit for detecting LAG-3 for the treatment or prevention of disease or immune response, and / or for the diagnosis, prognosis or monitoring of disease, comprising the single domain antibody of the present invention.Such a kit may include other components, packaging, instructions or materials useful for detecting LAG-3 protein.The kit may include a labeled single domain antibody or binding agent as described herein, and one or more compounds for detecting the label.
[0266] In another aspect, the present invention provides a single domain antibody or binding agent as described herein of the present invention packaged in lyophilized form or packaged in an aqueous medium.
[0267] The invention also relates to a single domain antibody or binding molecule as herein described with reference to the figures and examples.
[0268] In another embodiment, the single domain antibodies or binding molecules described herein are used for non-therapeutic purposes, such as diagnostic tests and assays. A method for detecting the presence of human LAG-3 in a test sample, such as serum or plasma, comprises contacting the sample with a single domain antibody described herein and at least one detectable label, and detecting binding of the single domain antibody to human LAG-3.
[0269] In one embodiment, the present invention relates to a method for diagnosing LAG-3 mediated adaptive immune resistance in a patient with cancer, comprising contacting a sample with a single domain antibody as disclosed herein, labeled with a detectable moiety; and detecting expression of LAG-3 on immune cells, such as CD4+ T cells, CD8+ T cells, T regulatory cells, B cells, NK cells and plasmacytoid dendritic cells. The sample may be tumor tissue.
[0270] The modification of antibodies for diagnostic purposes is well known in the art. For example, antibodies can be modified with ligand groups such as biotin, or detectable marker groups such as fluorescent groups, radioisotopes or enzymes. The compounds of the present invention can be labeled using conventional techniques. Suitable detectable labels include, but are not limited to, fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands with specific binding partners.
[0271] Unless otherwise defined herein, scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by those skilled in the art. The above disclosure provides a general description of the subject matter encompassed within the scope of the present invention, including the method of making and using the invention and the best mode thereof, but the following examples are provided to enable those skilled in the art to further practice the invention and to provide a complete description thereof. However, those skilled in the art will understand that the details of these examples should not be read as limiting the invention, the scope of which should be understood from the claims appended to this disclosure and their equivalents. Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of this disclosure.
[0272] All documents referred to herein are incorporated by reference in their entirety, including references to gene accession numbers and references to patent publications.
[0273] "And / or," as used herein, should be construed as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is considered a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, as if each were individually set forth herein. Unless the context indicates otherwise, the above feature descriptions and definitions are not limited to a particular aspect or embodiment of the present invention, but apply equally to all aspects and embodiments described.
[0274] The invention is further illustrated in the following non-limiting examples. EXAMPLES
[0275] Example 1. Construction of Tg / TKO mice Mice carrying human heavy chain antibody transgenic loci in germline configuration in a background in which endogenous heavy and light chain antibody expression was suppressed (triple knockout, or TKO) were grown as previously described (WO2004 / 076618, WO2003 / 000737, Ren et al., Genomics, 84, 686, 2004; Zou et al., J. Immunol., 170, 1354, 2003 and WO2016 / 062990). Briefly, transgenic mice were grown in a 30-mL oocyte culture medium (C. H Large amounts of human V1 domains combined with mouse immunoglobulin constant region genes lacking mouse enhancers and regulatory regions H Yeast artificial chromosomes (YACs) containing the A, D and J genes were used to generate the vectors following pronuclear microinjection of freshly fertilized oocytes. Yeast artificial chromosomes (YACs) are vectors that can be used for cloning very large DNA inserts in yeast. Not only do they contain all three cis-acting structural elements essential for behaving like a natural yeast chromosome (autonomously replicating sequence (ARS), centromere (CEN) and two telomeres (TEL)), but their ability to accommodate large DNA inserts allows them to reach the minimum size (150 kb) required for chromosome-like stability and fidelity of transmission in yeast cells. The construction and use of YACs are well known in the art (e.g., Bruschi, CV and Gjuracic, K. Yeast Artificial Chromosomes, Encyclopedia of Life Sciences, 2002, Macmillan Publishers Ltd., Nature Publishing Group / www.els.net).
[0276] The YACs used included multiple human heavy chain V genes, multiple human heavy chain D and J genes, mouse C H 1 gene and the mouse 3' enhancer gene. H It is missing one exon.
[0277] Transgenic founder mice were backcrossed with animals lacking endogenous immunoglobulin expression to generate the Tg / TKO lines used in the immunization studies described below.
[0278] Example 2. Antigens for immunization and characterization LAG-3 Human and monkey LAG-3 extracellular domains were produced as IgG fusion proteins for transgenic mouse immunization or binding studies. Human LAG-3 sequence accession NM_002286. Rhesus LAG-3 accession XM_001108923. The rhesus amino acid sequence matches the cynomolgus amino acid sequence for LAG-3 domains 1-3 (NC_022282). Mouse LAG-3 was from R&D Biotechne (catalog 3328-L3). Human LAG-3 domains 1-4 and 1-2 were cloned using standard molecular biology techniques. Domains were identified according to Huard et al 1997 PNAS 94:5744-9. Expression was performed in HEK293 cells and LAG-3 protein was purified using size exclusion chromatography. Chinese hamster ovary (CHO) cells expressing human LAG-3 were generated using the human LAG-3 sequence in an inducible expression vector. The plasmid was transfected using lipofection and stable cell pools selected with antibiotics. Cells expressing LAG-3 were sorted based on positive binding of a mouse anti-LAG-3 antibody (clone 17B4, Abcam).
[0279] PD-1 Immunization was performed using recombinant human PD-1 Fc chimera purchased from R&D, catalog number 1086-PD. A CHO cell line expressing human PD-1 on its surface was used for characterization.
[0280] Example 3. Immunization Protocol Each 8-12 week old Tg / TKO mouse was primed with 40 μg of recombinant purified human LAG-3-Fc protein emulsified in complete Freund's adjuvant and delivered subcutaneously, and then boosted three times at various intervals after this initial priming with 10 μg of recombinant protein emulsified in incomplete Freund's adjuvant, also delivered subcutaneously. A final dose of 20 μg of recombinant purified human LAG-3-Fc protein antigen was administered intraperitoneally in phosphate buffered saline in the absence of adjuvant.
[0281] For immunization to generate PD-1 blockers, each 8- to 12-week-old Tg / TKO mouse was administered an initial dose of 50 μg or 10 μg of recombinant purified human PD-1-Fc protein.
[0282] Example 4. Generation of anti-LAG3 library from immunized mice The construction of libraries from the above immunized mice followed standard protocols for library construction as summarized below: a) Tissue harvesting and homogenization, RNA extraction and RT-PCR Spleens, inguinal and brachial lymph nodes from several immunized mice were collected into RNAlater®. RNA was extracted from whole spleens using the Qiagen RNeasy® kit (catalog 74104) according to the manufacturer's protocol or via a Kingfisher automated system (Thermo) using the Pure RNA Tissue kit (catalog 98040496). VRNAs were extracted from RNA samples using the Superscript III RT-PCR Hi-Fi kit (Invitrogen catalog 12574-035) according to the manufacturer's protocol. H The sequence was pulled out.
[0283] b) Cloning into a phagemid vector In these studies, the phagemid vector pUCG3 was used. Conventional PCR-based methods were used to amplify the V H Sequence to V H The purified V H Use the RT-PCR products to prepare PCR reactions from linearized pUCG3 and cloned V H A heterogeneous population of
[0284] PCR products were analyzed on a 1% (w / v) agarose gel.
[0285] c) Construction of phagemid libraries V H The / phagemid PCR products were purified using the Fermentas PCR Purification Kit (catalog no. K0702) according to the manufacturer's instructions. The eluted DNA was used to transform TG1 E. coli (Lucigen, catalog no. 60502-2) by electroporation using a Bio-Rad GenePulser Xcell. Electroporated cells were pooled and plated onto large 2xTY agar bioassay dishes supplemented with 2% (w / v) glucose and 100 μg / ml ampicillin. All agar plates were incubated overnight at 30°C.
[0286] The library was harvested by adding broth to the large bioassay dishes to resuspend the colonies. The bacterial colonies were pooled and used in the phage selection process.
[0287] Example 5.V H Selection strategy for the isolation of Preparation of library phage stocks and phage display selection were performed according to published methods (Antibody Engineering, edited by Benny Lo, chapter 8, p161-176, 2004). In most cases, phage display combined with a panning approach was used to identify binding V H The domains were isolated. However, a variety of different selection methods are well described in the art, including soluble selection and selection under stress (e.g., heat).
[0288] Example 6. Form Each V confirmed to bind to LAG-3 recombinant protein or LAG-3-expressing CHO cells H The clones were sequenced from the phagemid and H Grouping was based on germline and CDR3 amino acid similarity.
[0289] Periplasmic extracts were screened for binding to CHO human PD-1 cells and inhibition of PD-L1-bound PD-1. Following library selection, specific Vs were identified that bound to CHO cells expressing human PD-1 and inhibited the interaction between recombinant human PD-1 protein and recombinant human PD-L1 protein. H was identified by single-point screening of bacterial periplasmic extracts. V binds to CHO human PD-1 cells with FL2 fluorescence >1000 and inhibits PD-1 binding to PD-L1. H A family was identified.
[0290] The bivalent construct for LAG-3 binding is V HThe constructs were generated by PCR assembly, with a glycine-serine linker between the two. The assembled constructs were cloned into DNA vectors for expression in microbial cells. Examples of such sequences with different linkers are shown below. Each of the constructs used in the experiments further contained a C-terminal sequence with three alanines and a His tag of six histidines.
[0291] SEQ ID NO:251 V H 1.1-6GS-V H 1.1-6GS-V H 2.63-His6 EVQLVESGGGVVRPGGSLRLSCSASGTFFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARIPREDCSSASCYTD AIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCSASGTFFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGR FTISRDNAKNSLYLQMNSLRAEDTALYYCARIPREDCSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSC AASGFTFSDSSMTWMRQAPGKGLEWVSYISSGGGVKFYTDSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYYCAREAPLRLGESPHDAFDISGQGTMVTVSSAAAHHHHHH
[0292] SEQ ID NO:252 V H 1.1-6GS-V H 1.1-9GS-V H 2.63-His6 EVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDN AKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFSDSSMTWMRQAPGKGLEWVSYISSGGGVKFYTDSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYCAREAPLRLGESPHDAFDISGQGTMVTVSSAAAHHHHHH
[0293] sequence no. 253 V H 1.1-6GS-V H 1.1-His6 EVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGG SGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSAAAHHHHHH
[0294] sequence no. 254 V H 1.1-4GS-V H 1.1-His6 EVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGG SGGGGSEVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSAAAHHHHHH
[0295] sequence no. 255 V H 1.1-8GS-V H 1.1-His6 EVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGG SGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSAAAHHHHHH
[0296] sequence no. 256 V H 1.1-12GS-V H 1.1-His6 EVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGSGGGSGGGSGGGG SGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSAAAHHHHHH
[0297] sequence no. 257 V H 2.77-9GS-V H 1.1-6GS-V H 1.1-His6 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDSSMTWMRQAPGKGLEWVSYISSGGGVKFYTDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYCAREAPLRLGESPHDAFDISGQGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGGSGGGSGGGSGGGSEVQLVESGGGVVRPGGSLRLSCSASGFFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYA DSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGVVRPGGSLRLSCSASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGNSGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGPGTMVTVSSAAAHHHHHH
[0298] sequence no. 258 V H1.2-6GS-V H 1.2-6GS-V H 2.92-His6 EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGQGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGSTGYADSVKGR FTISRDNAKNSLYLQMNSLRAEDTALYCARIPREDCSSSASCYTDAIDFWGQGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFSDESMTWMRQAPGKGLEWVSYISSGGGVKFYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYCAREAPLRLGESPHDAFDISGQGTMVTVSSAAAHHHHHH
[0299] sequence no. 259 V H 1.2-6GS-V H 1.2-6GS-V H 2.92 EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARIPREDCSSASC YTDAIDFWGQGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGIHWNGGSTGYAD SVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARIPREDCSSASCYTDAIDFWGQGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPG GSLRLSCAASGFTFSDESMTWMRQAPGKGLEWVSYISSGGGVKFYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREAPLRLGESPHDAFDISGQGTMVTVSS
[0300] V is a nucleotide sequence that is modified to revert portions of the sequence back to the germline, improve conjugation kinetics, or remove biophysical hindrances such as isomerization or deamidation. H Mutations were added to 1.1. Individual mutations or randomization were achieved using standard overlap extension PCR techniques. H 1.2 (SEQ ID NO:8) is an example of such a sequence.
[0301] Bispecific constructs were generated by PCR assembly. Table 5 shows the amino acid sequences of PD-1 clones that can be combined with the sequences in Table 1 in any orientation using linkers. The corresponding nucleic acid sequences are also provided herein. The assembled constructs were cloned into DNA vectors for expression in microbial cells.
[0302] Example 7. Purification V H Preparation of Humabody® V Hwas expressed in a microbial cell system. The protein was isolated from the cell supernatant using affinity purification. The yield of the purified protein was estimated spectrophotometrically and the purity was assessed using UPLC-SEC. The stability was assessed by incubation at 40°C overnight and analyzed by size exclusion chromatography. Briefly, the purified V H were stored at 3-10mg / ml in PBS buffer at 4-40°C and separated on a Waters ACQUITY BEH125Å SEC column and analyzed using a Waters H-Class Bio UPLC with a PDA detector (detection at 280nm). Samples were injected in a volume of 10μl and run at a flow rate of 0.4ml / min with a mobile phase containing 200mM NaCl, 100mM sodium phosphate, pH 7.4 + 5% propan-1-ol. Data were collected for 6 minutes and the percentage of monomer remaining after storage was calculated compared to that present at the start (T=0).
[0303] V of 10mg / ml H 1.1 was incubated at 40°C for 14 days, and size exclusion chromatography showed that V H The purity of the peak was shown to be 97.67%.
[0304] V of 3mg / ml H 1.1-6GS-V H When 1.1 was incubated overnight at 40° C., the peak area was 100.1% of T=0. When 1.5 mg / ml of 1.1-6GS-1.1-9GS-2.63 was incubated overnight at 40° C., the peak area was 100.34% of T=0. Thus, these forms show excellent stability.
[0305] Example 8. Binding properties of constructs Refined V Hwere tested for their binding ability to human LAG-3 (R&D Systems Cat. No. 2319-L3), rhesus monkey LAG-3 (see Example 2), mouse LAG-3 (Sino Biological Cat. No. 53069-M02H), human LAG-3 domains 1-2 (see Example 2), CHO cells expressing human LAG-3, human PD-1 (R&D Systems Cat. No. 1086-PD) and activated T cells.
[0306] To screen for binding to CHO cells expressing human LAG-3, reagents were prepared in FMAT assay buffer (pH 7.4) containing PBS, 0.1% bovine serum albumin, and 0.01% sodium azide. H The wells were transferred to a 384-well assay plate (Costar Cat. No. 3655) and incubated for 2 hours with 2000 CHO human LAG-3 cells (Thermo Scientific Cat. No. 62251) prestained with 1.5 nM anti-His (Millipore Cat. No. 05-949) / 3 nM goat anti-mouse Alexa Fluor-488 (Jackson Immunolabs Cat. No. 115-545-071) and DRAQ5. Plates were read in the FL2 (502 nm-537 nm) and FL5 (677-800 nm) channels of a TTP Mirrorball plate reader after excitation at 488 nm and 640 nm. Data were gated at the border and peak intensity of FL5, and the mean fluorescence intensity of the FL2 median of the gated data was calculated as V H Used to determine binding. H 1.1 showed binding to LAG-3 expressed in CHO cells with an average EC50 of 1.8E-09M, n=2.
[0307] To screen for specificity by ELISA, antigens were coated at 1-5ug / ml and blocked with Marvel milk powder. Hwas added at 10 μg / ml and incubated for 1 hour. After washing, HRP-labeled anti-HIS antibody (Miltenyi Cat. No. 130-092-785) was added. A colorimetric signal was generated using TMB substrate and acidic solution. H 1.1 and V H 1.1-6GS-V H 1.1 bound to human LAG-3, cynomolgus monkey LAG-3 and human LAG3 domains 1-2 with a signal over 10-fold above background. They showed no binding to mouse LAG-3, human IgG1, mouse IgG2a or the closely related antigen, CD4 (R&D Biotechne 514-CD). 1.2-6GS-1.2-6GS-2.92 showed no binding to CD4, CD28, CTLA4 proteins when tested with the real-time biolayer interferometer-based biosensor Octet (ForteBio).
[0308] Binding kinetics were measured with a real-time biolayer interferometer-based biosensor Octet (ForteBio). Recombinant human LAG-3-Fc was immobilized by standard amine coupling to an amine-reactive biosensor in 10 mM sodium acetate at pH 5.0. All binding studies were performed in HBS-ET Octet kinetic buffer. The biosensor was washed with Octet kinetic buffer between the different steps. Each Humabody® V H A seven-point two-fold dilution series of was made with a highest concentration of 1.6 μM. The contact time for each association step was 150 s and the dissociation step was 300-400 s. Kinetic association (ka) and dissociation (kd) rate constants were determined by processing the data and fitting to a 1:1 binding model using ForteBio Analysis software. The calculated affinity constants for selected sequences are shown in Table 6 below.
[0309] [Table 6]
[0310] Multivalent and bispecific V H The binding kinetics of each Humabody® V was also measured with a real-time biolayer interferometer-based biosensor Octet (ForteBio). Recombinant human LAG-3-Fc or domains 1-2-Fc were immobilized by a protein G biosensor. All binding studies were performed in HBS-ET Octet kinetic buffer. The biosensor was washed with Octet kinetic buffer between the different steps. H A seven-point two-fold dilution series of LAG-3 was made with a top concentration of 25 nM (full-length LAG-3, or truncated 400 nM). The contact time for each association step was 150 s and the dissociation step was 400 s. To measure the kinetics of cynomolgus LAG-3, the protein was immobilized using the ARG2 sensor in 10 mM sodium acetate at pH 5 and V H The concentration started at 1.6 μM and the association time was 180 seconds. To compare the constructs, the kinetic association (ka) and dissociation (kd) rate constants were determined by processing and fitting the data to a 1:1 binding model using ForteBio Analysis software. The values are shown in Table 7.
[0311] [Table 7]
[0312] Binding to PD-1 was measured by HTRF (homogeneous time-resolved fluorescence). Serial dilutions of the HIS-tagged constructs were prepared in assay buffer containing PBS, 0.1% BSA and 0.4 M potassium fluoride. Samples or assay buffer (non-specific binding) were incubated in the plate with 1–2 nM human LAG-3-Fc / PD-1-Fc, 1 nM anti-human-Fc cryptate PAb (Cisbio Cat. No. 61HFCKLB) and 15 nM anti-His-D2 (CisBio Cat. No. 61HISDLA) for a minimum of 3 h at room temperature. Time-resolved fluorescence emission at 620 nm and 665 nm was measured after excitation at 337 nm on a BMG PHERAstar plate reader. HTRF ratios were calculated ((665 nm emission / 620 nm emission) * 10000) and the data was corrected for (non-specific binding) to obtain the specific binding signal. EC50s were calculated from the titration curves (Table 8 below).
[0313] [Table 8]
[0314] Binding of 1.2-6GS-1.2-6GS-2.92 to proteins was measured using a biolayer interferometer-based biosensor Octet (ForteBio). LAG-3 antigen was coupled to the ARG2 sensor via amine coupling and samples were tested in a dilution series. PD-1 antigen was captured using a Protein G sensor. Affinity measurements are shown in Table 9.
[0315] [Table 9]
[0316] The ability of the construct to bind both targets simultaneously was demonstrated using the biolayer interferometer-based biosensor Octet (ForteBio). Recombinant LAG3-Fc (10 μg / ml) was immobilized by standard amine coupling to an amine-reactive biosensor in 10 mM sodium acetate at pH 6. Binding steps were performed in 0.1% BSA and 0.02% Tween 20 in PBS. 100 nM Humabody® was used in the first binding step, followed by 5 μg / ml human PD1-Fc. The contact time for association and dissociation was 200 s. Figure 1 shows the binding of 1.1-6GS-1.1-6GS-2.63 to LAG-3 and PD-1.
[0317] Binding to cell surface targets was demonstrated using a cell line developed by DiscoverX. Human LAG-3 and human PD-1 were expressed on the surface of the cells and their intracellular domains were fused to the enzyme fragments. Receptor dimerization forced the complementation of the enzyme fragments and the addition of substrate generated a chemiluminescent signal. EC50 was calculated from the fold increase in relative light units over background and is shown in Table 10. The bispecific molecules showed higher signals and improved EC than bispecific antibodies with larger cross-coordinates, indicating the potential of dual-engagement.
[0318] [Table 10]
[0319] Binding of Humabody® constructs to LAG-3 and PD-1 antigens was determined using Dynamic Biosensors switchSENSE technology with dual color detection. Antigens were covalently attached to the biosensor surface using amine coupling methods, with each antigen linked to a different nanolever with a red or green fluorescent tag. Binding of bispecific constructs was measured for either the individual antigens alone or when both antigens were simultaneously present on the surface. The kinetics of interaction with each antigen are shown in Table 11.
[0320] In the presence of PD-1, conjugation of 1.2-6GS-1.2-6GS-2.92 with LAG-3 improved the affinity KD by 68-fold. In the presence of LAG-3, there was a 107-fold improvement in KD for binding to PD-1, demonstrating that the bispecific enhances affinity for the target when both are present.
[0321] [Table 11]
[0322] Binding to human activated T cells was measured by cytometry. PBMCs or magnetically separated T cells were isolated from leukocyte cones and cells were cultured in 96-well plates coated with 5 μg / ml anti-CD3 (OKT3). Anti-CD28 (CD28.2) was added at 1 μg / ml in RPMI medium and fetal bovine serum. After 72–96 h, cells were harvested and stained using standard flow cytometry methods. Humabody® constructs were titrated in a 3-fold series and detected using anti-HIS-biotin (Biotechne BAM050) and streptavidin Alexa-Fluor 488 (ThermoFisher). Fluorescently labeled anti-CD4 and anti-CD8 were included in the PBMC cultures and live / dead dyes. Stained cells were analyzed using an IQue cytometer (Intellicyte). EC50 was calculated from titration curve of Humabody median fluorescence and gated on CD4+ or CD8+ cells when using mixed cells. For cynomolgus cells, pan T cells were isolated using magnetic separation and stimulated with CD3 / CD28 beads (Miltenyi) according to the manufacturer's instructions. After 72 hours in culture, cells were stained similarly to human cells for flow cytometry. EC50 was calculated from titration curve of percentage of CD4 or CD8 that were positive. Table 12 shows EC50 for T cell binding. The bispecific shows strong binding to human T cells and cross-reactivity with monkeys. Monovalent LAG-3 V H1.1 binds weakly to cells whereas the bivalent form enhances this, see FIG.
[0323] The bispecific binders show higher median fluorescence than either the PD-1 or LAG-3 components alone (Figure 2). This may suggest binding to LAG3+, PD1+ and LAG3+PD1+ cells. The bispecific binders target double-positive cells with higher avidity than single-positive cells.
[0324] [Table 12]
[0325] Example 9. Inhibition of Ligands a) PD-1:PD-L1 inhibition The ability of Humabody® to inhibit functional responses in transfected Jurkat cells as a result of PD-1:PD-L1 blockade was assessed using an NFAT-luciferase reporter gene assay. Jurkat reporter cell lines expressing human PD-1 and a luciferase reporter gene under the control of a promoter with an NFAT response element, and CHO cell lines expressing activator of T cell receptor and human PD-L1 under the control of a tetracycline-inducible promoter were generated using standard methods.
[0326] CHO human PD-L1 / TCR activator cells were seeded at 10000 cells / well in a 96-well white plate. Plates were incubated overnight at 37°C in a 5% CO2 incubator. Samples were serially diluted in assay medium (RPMI+2%FBS). Jurkat PD-1 reporter cells were diluted in assay medium at 5e5 cells / ml. Medium was removed from the CHO cells and 50μl of diluted sample or assay medium (background control) was added to the plate followed by 50μl of diluted Jurkat reporter cells. Plates were incubated at 37°C in a CO2 incubator for 6 hours, removed from the incubator and equilibrated at room temperature for 20 minutes. NanoGlo substrate (100μl of substrate diluted 1:50 in NanGlo buffer (Promega Cat# N1120)) was added and the plate was incubated at room temperature for 20 minutes before measuring luminescence signal (RLU). Data are expressed as fold / background signal.
[0327] Humabody® V H demonstrated a dose-dependent enhancement of luciferase signal in the assay indicating blockade of the PD-1:PD-L1 interaction. EC50s were calculated from nonlinear regression curve fits of fold / background and data for selected clones and constructs are shown in Table 13.
[0328] The potency of the bispecific construct against PD-1 positive cells is more than 30-fold lower than monoclonal antibodies. This represents an advantage in vivo, where non-specific T cells can be activated by anti-PD-1. The low potency against single PD1+ cells and the high potency against PD1+LAG3+ cells allows the ability to target specific "exhausted" T cells.
[0329] [Table 13]
[0330] Purified monovalent V Hwere tested for their ability to inhibit PD-L1 binding to CHO human PD-1 cells using an FMAT inhibition assay.
[0331] All reagents and serial dilutions were H was prepared in FMAT assay buffer. H , buffer (total binding control) or excess competitor (non-specific binding control) were incubated with 100 pM human Fc-tagged human PDL-1, 3 nM anti-human Fc-Alexa Fluor-488 and 2000 CHO human PD-1 DRAQ5 stained cells per well in a 384-well black clear bottom assay plate. After incubating the plate at room temperature for 2 h, fluorescence was measured in the FL2 (502 nm-537 nm) and FL5 (677-800 nm) channels of a Mirrorball plate reader (TTP) after excitation at 488 nm and 640 nm. After subtracting the background signal determined from the non-specific binding control wells, data were expressed as % of total binding control (i.e., % control). IC50s are shown in Table 14, with the monovalent anti-PD-1 V H have highly similar sequences and activities.
[0332] [Table 14]
[0333] b) LAG-3: MHCII inhibition LAG-3: Inhibits T cell functional responses as a result of MHCII inhibition HThe ability of was assessed using an NFAT-luciferase reporter gene assay (Promega LAG-3 assay). A Jurkat reporter cell line expressing human LAG-3 and a luciferase reporter gene under the control of a promoter with an NFAT response element was incubated with the Raji B cell line expressing MHC class II. When T cells are stimulated by adding the T cell activator Staphylococcal enterotoxin D and LAG-3:MHCII is blocked by an antibody such as 17B4, the luciferase signal increases.
[0334] Samples were serially diluted and reagents were added according to the manufacturer's instructions. Luminescence signal (RLU) was read after 6 hours. Data were expressed as fold / background signal.
[0335] Humabodies® potentiate NFAT signaling in assays showing blockade of LAG-3:MHCII interactions. EC50s were calculated from fold / background nonlinear regression curve fits and data for selected clones and constructs are shown in Table 15.
[0336] [Table 15]
[0337] c) Alternative Ligand Inhibition Galectin-3 (Peprotech Cat. No. 450-38-100), Resectin (R&D systems Cat. No. 2947-CL) or α-synuclein (R&D systems Cat. No. SP480-500) were coated onto maxisorp ELISA plates at 1-2 μg / ml. Plates were blocked with 3% Marvel skim milk powder in PBS. LAG-3-Fc was added to the coated plates in V HThe plates were pre-incubated with HRP for 1 hour. LAG-3 binding was detected using anti-human IgG conjugated to HRP. Three washing steps were performed with PBS 0.05% Tween. Color was developed using TMB and 0.5M sulfuric acid solution. Humabody® V specific for LAG-3 was used. H Blocked LAG-3:galectin, LAG-3:resectin and LAG3:α-synuclein interactions. EC50s were calculated from absorbance fitted to non-linear regression curves and example data are shown in Table 16. Unrelated V binding to PD-1 H did not inhibit these interactions.
[0338] [Table 16]
[0339] Example 10. Enhancement of immune cell function a) Superantigen assay PBMCs from healthy human donors were isolated from leukocyte cones using density gradient centrifugation. PBMCs were stimulated with 10-100ng / ml Staphylococcal Enterotoxin B (SEB) for 2-3 days. Cells were restimulated with various concentrations of SEB in the presence of antibodies or Humabody®. IL-2 secreted into the supernatant was measured using HTRF (Cisbio Human IL-2 kit Cat. No. 64IL1PEB). Bivalent V H1.1-6GS-1.1 enhanced T cell stimulation by combining with PD-1 blockade (Figure 3a). The bivalent Humabody alone only minimally enhanced over the Humabody® negative control or the IgG negative control. Humabody® 1.1-6GS-1.1-9GS-2.63 enhanced T cell stimulation over the benchmark PD-1 and LAG-3 antibodies (Figure 3b). 1.2-6GS-1.2-6GS-2.92 showed similar enhancement over the benchmark (relatolimab and nivolumab analogs). Humabody® 1.1-6GS-1.1-9GS-2.63 enhanced T cell stimulation over the combination of its components (Figure 3c). The two LAG-3 V H The bispecific form contains one LAG-3 V H The asymmetric morphology stimulated IL-2 production more than the LAG-3:PD1-containing morphology (Figures 3d and 3e). This data indicates that the asymmetric morphology has a functional advantage over other LAG-3:PD1 binding morphologies. Figure 3f shows the induction of proinflammatory cytokines, IL-2, TNF-α and interferon-γ after 6 days in culture.
[0340] b) Antigen-specific assays PBMCs from eight human donors were used in the CMV peptide stimulation system. PBMCs were pulsed with a pool of CMV peptides for 1 hour and Humabody® was added prior to incubation. Cells were cultured in the presence of 25ng / ml IL-7 and 10U / ml IL-2. On day 5, cells were washed and stained for flow cytometry. Cells were stained using CMV tetramers of different HLA types and the percentage of CD8+ tetramer+ cells was calculated. The fold increase in percentage was compared to irrelevant V H Figure 4 shows that treatment with the bispecific 1.1-6GS-1.1-9GS-2.63 increases proliferation. In some responses, the bispecific acts as a dual paratopic PD-1 binder (two V-binding sites on PD-1). H (binding to LAG-3) and bivalent LAG-3 do not.
[0341] Example 7. In vivo efficacy 24 hu-PBMC NCG mice were treated with 5 × 10 6 Seven days before subcutaneous implantation of RKO colon cancer cells, 3 x 10 cells were injected into the mouse by tail vein injection. 7 hPBMCs were transplanted. When tumors became palpable, measurements were started with a digital caliper, and tumor volumes were measured twice a week. When tumor volumes were approximately 30–60 mm 3 Upon reaching tumor volume, mice were randomized based on tumor volume. Mice were dosed starting on study day 1 according to Table 17. A number of agents were tested, as shown in Table 17.
[0342] Body weight, clinical observations and digital caliper measurements were recorded twice weekly after dosing began. Bispecifics can mediate inhibition of tumor growth (Figure 5). MSA binds to serum albumin in mice by binding to V H HEL4 is a negative control that does not bind to the target. H It is.
[0343] [Table 17]
[0344] Example 8. Patient T cell expansion 1.2-6GS-1.2-6GS-2.92 can rescue T cells in a patient ex vivo cell system that models the interaction of cancer cells and T cells. PBMCs from NSCLC patients were incubated with a lung adenocarcinoma cell line that provides weak TCR stimulation with anti-CD3. In CD4+ and CD8+ cells, the percentage of Ki67+ proliferating cells increased in the presence of 1.2-6GS-1.2-6GS-2.92. This was significantly higher than treatment with PD-1 antibody, which only slightly increased proliferation (Figure 6). These patients may not respond to PD-1 antibody treatment, so the stimulation of T cell proliferation provided by the bispecific is beneficial. The bispecific also promoted proliferation more than combination treatment in cells from four patients (Table 18).
[0345] [Table 18]
[0346] Example 9. Suppression of inhibitory signaling CD4 or CD8 T cells from NSCLC patients were incubated with a human lung adenocarcinoma cell line (A549) that provides weak TCR stimulation. Cultures were incubated with LAG-3 bivalent, PD-1 monovalent or PD-1 monovalent antibodies or with equal concentrations of LAG-3 bivalent and PD-1 monovalent V H and compared these to the bispecific 1.2-6GS-1.2-6GS-2.92. Cells were analyzed for expression of the negative T cell regulators CBL-b and c-CBL by flow cytometry. The percentage of cells or the mean fluorescence intensity of cells expressing the E3 ubiquitin ligases Cbl-b (Uniprot accession number Q13191 or NCBI reference NP_001308717.1) and c-Cbl (also known as C-CBL, CBL, Uniprot P22681) was calculated, Table 19. E3 ubiquitin ligases have been implicated in the PD-1 / PD-L1 signaling pathway (Karwacz et al, EMBO MOl Med 3, 581-592, 2011).
[0347] [Table 19]
[0348] PD-1 blockade reduced Cbl-b in CD4+ T cells, whereas LAG-3 bivalent had no effect. Combination of PD-1 and LAG-3 blockade had no additional effect compared to PD-1 blockade alone. The bispecific significantly inhibited Cbl-b and c-cbl expression in both CD4+ and CD8+ T cells from NSCLC patients. Thus, consistent with the data shown in Figure 6 on proliferation, bispecific target binding allows suppression of biomarkers of T cell inhibitory signaling, unlike combination therapy. The only therapy that reduced c-Cbl and Cbl-b protein expression was the bispecific, suggesting that bispecific binding to dual targets allows alternative signaling pathways compared to combination therapy.
Claims
1. An isolated human heavy chain variable domain (V) that binds to human LAG-3, comprising a CDR3 sequence selected from SEQ ID NO: 3 or 7, or a sequence having at least 70%, 80% or 90% homology thereto. H ) Single domain antibodies.
2. 2. The isolated VH polypeptide of claim 1, comprising a CDR1 as set forth in SEQ ID NO:1 or a sequence having at least 70%, 80% or 90% homology thereto, a CDR2 as set forth in SEQ ID NO:2 or a sequence having at least 70%, 80% or 90% homology thereto, and a CDR3 as set forth in SEQ ID NO:3 or a sequence having at least 70%, 80% or 90% homology thereto. H Single domain antibodies.
3. 3. The isolated VH polypeptide of claim 2, comprising a CDR1 as set forth in SEQ ID NO:5 or a sequence having at least 70%, 80% or 90% homology thereto, a CDR2 as set forth in SEQ ID NO:6 or a sequence having at least 70%, 80% or 90% homology thereto, and a CDR3 as set forth in SEQ ID NO:7 or a sequence having at least 70%, 80% or 90% homology thereto. H Single domain antibodies.
4. 2. A single domain antibody as described in claim 1, comprising a sequence selected from SEQ ID NO: 4 or 8, or a sequence having at least 70%, 80% or 90% homology thereto.
5. 5. The isolated single domain antibody of any one of claims 1 to 4, wherein said single domain antibody is conjugated to a toxin, an enzyme, a radioisotope, a half-life extending moiety, a label, a therapeutic molecule or other chemical moiety.
6. 7. The isolated single domain antibody of claim 6, wherein the half-life extending moiety is selected from the group consisting of an albumin binding moiety, a transferrin binding moiety, a polyethylene glycol molecule, a recombinant polyethylene glycol molecule, human serum albumin, a fragment of human serum albumin, and an albumin binding peptide or a single domain antibody that binds to human serum albumin.
7. 7. The isolated single domain antibody of any one of claims 1 to 6, which is obtained or obtainable from a transgenic rodent expressing a transgene comprising human V, D and J regions.
8. 8. The isolated single domain antibody of claim 7, wherein the rodent does not produce functional endogenous light and heavy chains.
9. The first (V H ) single domain antibody, and a second (V H 2.) An isolated binding agent comprising a single domain antibody.
10. The first and / or second (V H 10. The isolated binding agent of claim 9, wherein the single domain antibody is selected from the isolated single domain antibodies of any one of claims 1 to 8.
11. 10. A binding agent comprising the isolated binding agent of claim 9 or the single domain antibody of any one of claims 1 to 8 linked to a second functional moiety having a binding specificity different from that of the single domain antibody.
12. 12. The isolated binding agent of claim 11, wherein the second functional moiety does not bind to LAG-3.
13. 13. The isolated binding agent of claim 11 or 12, wherein the second binding molecule is an antibody or a fragment thereof.
14. The fragment may be a Fab, Fab', F(ab')2, dAb, Fd, Fv, or single chain Fv fragment, a human heavy chain variable domain (V H ), or an isolated CDR.
15. The second functional portion has SEQ ID NO: 4 or SEQ ID NO: 8 H 15. The isolated binding agent of claim 14 which is a single domain antibody.
16. The V according to any one of claims 1 to 8 H 16. A multispecific binding agent comprising a single domain antibody or a binding agent of any one of claims 9 to 15 and a second functional moiety that binds to PD-1.
17. The multispecific binding agent of claim 16, wherein the second functional moiety that binds to PD-1 is an antibody or fragment thereof.
18. The fragment may be a Fab, Fab', F(ab')2, dAb, Fd, Fv, or single chain Fv fragment, V H 18. The multispecific binding agent of claim 17 which is a human heavy chain variable domain or isolated CDRs.
19. The second functional moiety that binds to PD-1 is V H The multispecific binding agent of any one of claims 16 to 18, which is a single domain antibody.
20. V that binds to PD-1 H Single domain antibodies may be used in combination with any of the V domain antibodies listed in Table 5. H 20. The multispecific binding agent of claim 19 selected from single domain antibodies.
21. V that binds to PD-1 H A single domain antibody is H 21. The multispecific binding agent of claim 20, selected from 2.63, 2.77 or 2.
92.
22. Two Vs that bind to LAG-3 H 22. The multispecific binding agent of claim 21 , comprising a single domain antibody.
23. Two Vs that bind to LAG-3 H 23. The multispecific binding agent of claim 22, wherein the single domain antibody has SEQ ID NO: 8 or a sequence having at least 70%, 80% or 90% homology thereto.
24. 24. The binding agent of any one of claims 9 to 23, conjugated to a toxin, enzyme, radioisotope, half-life extending moiety, therapeutic molecule or other chemical moiety.
25. 25. The binding agent of claim 24, wherein the half-life extending moiety is selected from the group consisting of an albumin binding moiety, a transferrin binding moiety, a polyethylene glycol molecule, a recombinant polyethylene glycol molecule, human serum albumin, a fragment of human serum albumin, and an albumin binding peptide or a single domain antibody that binds to human serum albumin.
26. 26. The binding agent of any one of claims 9 to 25, wherein the moiety is linked with a (G4S)n linker, where n=1-20.
27. Use of a single domain antibody according to any one of claims 1 to 8 in a multivalent binding agent.
28. 28. The use of a single domain antibody according to claim 27, wherein said multivalent binding agent is multispecific.
29. 29. The use of a single domain antibody according to claim 28, wherein said multispecific binding agent binds to LAG-3 and PD-1.
30. An immunoconjugate comprising a single domain antibody according to any one of claims 1 to 8 or a binding agent according to any one of claims 9 to 26 linked to a therapeutic agent.
31. A pharmaceutical composition comprising a single domain antibody according to any one of claims 1 to 8, a binding agent according to any one of claims 9 to 26, or an immunoconjugate according to claim 30, and a pharmaceutical carrier.
32. A method of treating cancer, immune disorders, neurological disorders, inflammatory disorders, allergies, transplant rejection, viral infections, immunodeficiencies or other immune system related disorders comprising administering a therapeutically effective amount of a single domain antibody according to any one of claims 1 to 8, a binding agent according to any one of claims 9 to 26, or an immunoconjugate according to claim 30, or a pharmaceutical composition according to claim 31.
33. 32. Use of a single domain antibody according to any one of claims 1 to 8, a binding agent according to any one of claims 9 to 26, or an immunoconjugate according to claim 30, or a pharmaceutical composition according to claim 31, in the manufacture of a medicament for the treatment of cancer, an immune disorder, a neurological disorder, an inflammatory disease, allergy, transplant rejection, an infectious disease, an immunodeficiency or other immune system related disease.
34. A single domain antibody according to any one of claims 1 to 8, a binding agent according to any one of claims 9 to 26, or an immunoconjugate according to claim 30, or a pharmaceutical composition according to claim 31, for use as a medicament.
35. A single domain antibody according to any one of claims 1 to 8, a binding agent according to any one of claims 9 to 26, or an immunoconjugate according to claim 30, or a pharmaceutical composition according to claim 34, for use in the treatment of cancer, immune disorders, neurological disorders, inflammatory disorders, allergies, transplant rejection, viral infections, immunodeficiencies and other immune system related disorders.
36. 33. The method of claim 32, the use of claim 33, or the single domain antibody, binding agent or pharmaceutical composition of claim 31, wherein the cancer is selected from osteosarcoma, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, breast cancer, brain cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, kidney cancer, soft tissue sarcoma, urethral cancer, bladder cancer, renal cancer, lung cancer, non-small cell lung cancer, thymoma, urothelial carcinoma, leukemia, prostate cancer, mesothelioma, adrenocortical carcinoma, lymphomas such as Hodgkin's disease, non-Hodgkin's disease, gastric cancer, and multiple myeloma and other leukemias.
37. A method of modulating an immune response comprising administering a single domain antibody according to any one of claims 1 to 8, a binding agent according to any one of claims 9 to 23, or an immunoconjugate according to claim 30, or a pharmaceutical composition according to claim 31.
38. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a single domain antibody according to any one of claims 1 to 8 or a binding agent according to any one of claims 9 to 26.
39. 39. The isolated nucleic acid molecule of claim 38, selected from SEQ ID NO: 10 or 11.
40. A vector comprising the nucleic acid of claim 38 or 39.
41. 41. A host cell comprising a nucleic acid according to claim 35 or 36 or a vector according to claim 40.
42. 42. The host cell of claim 41, wherein the host cell is a bacterial, yeast, viral, plant or mammalian cell.
43. A method for producing a single domain antibody according to any one of claims 1 to 8, comprising expressing a nucleic acid encoding a binding molecule in a host cell and isolating said binding molecule from said host cell.
44. A kit comprising a single domain antibody according to any one of claims 1 to 8, a binding agent according to any one of claims 9 to 26, or an immunoconjugate according to claim 30, or a pharmaceutical composition according to claim 31.
45. 10. A method for detecting the presence of human LAG-3 in a test sample, comprising contacting the sample with a single domain antibody according to any one of claims 1 to 8 and at least one detectable label, and detecting binding of the single domain antibody to human LAG-3.
46. A combination therapy comprising administering a single domain antibody according to any one of claims 1 to 8 together with a second therapeutic agent.
47. 27. A method of simultaneously inhibiting immune checkpoints PD-1 and LAG-3 comprising administering a binding agent according to any one of claims 16 to 26.
48. A method for modifying or blocking the interaction of LAG-3 with galectin-3, resectin or α-synuclein comprising administering a single domain antibody of any of claims 1 to 8 or a binding agent of any of claims 9 to 26.
49. A method for modifying or blocking the interaction of LAG-3 with galectin-3, resectin or α-synuclein, comprising contacting LAG-3 with a single domain antibody of any of claims 1 to 8 or a binding agent of any of claims 9 to 26.
50. A CAR comprising a single domain antibody according to any one of claims 1 to 8 or a binding agent according to any one of claims 9 to 26.
51. 27. A method of selectively targeting cells that present PD-1 and LAG-3 on their surface, or increasing targeting of such cells compared to cells that present PD-1 on their surface, comprising providing a binding agent of any one of claims 9-26.
52. 52. The method of claim 51, wherein the method is in vitro, in vivo or ex vivo.
53. A method for identifying subjects who will respond to therapy with a bispecific agent that binds LAG-3 and PD-1 by measuring protein or RNA expression of Cbl-b and / or c-Cbl in the subject or a sample from the subject that has received the bispecific therapy.
54. The method of claim 53, wherein the therapy is with a binding agent according to any one of claims 9 to 26.
